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Disease modelling has enabled researchers to study a wide range of human diseases in the 
laboratory, overcoming many challenges. Parkinson Disease (PD) is a progressive 
neurodegenerative disorder that affects 1 to 2% of the human population over 65 years old, 
influencing cognitive ability and motor function. It is characterized by the inadequate function or 
the loss of dopamine-producing neurons of the substantia nigra pars compacta in the human 
midbrain.  Impairment of several genes has been associated with disease progression. Recently, a 
polymorphism in Oculocerebrorenal Syndrome of Lowe protein (Ocrl), was identified as a risk 
factor for PD. As Ocrl is very well-conserved between mammals and insects, I have used D. 
melanogaster to create an Ocrl-dependant model of human PD. Ocrl is the D. melanogaster 
orthologue of human Ocrl, a PtdIns(4,5)P2 phosphatase encoding gene in which mutant forms can 
result in the X-linked disorder known as Oculocerebrorenal Lowe Syndrome. Directed 
manipulation of the single D. melanogaster version of Ocrl in neurons that include dopaminergic 
neurons was performed in order to produce an in vivo model of the development and progression 
of a unique version of PD. The directed loss of function of Ocrl in dopaminergic neurons, through 
the use of RNAi, resulted in a decreased locomotor ability and median lifespan of the flies over 
time. In complementary experiments, the directed interference of Ocrl expression in the 
developing eye, led to a reduction in the number of ommatidia and interommatidial bristles. 
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Overexpression of Ocrl using D42 Gal4 and ddc Gal4 decreased lifespan, locomotor ability, the 
number of ommatidia and interommatidial bristles and increased lifespan by using TH Gal4. 
Crossing Ocrl with recombinant Ddc-GAL4/CyO; UAS-park RNAi/TM3 reduced lifespan 
overtime. Further investigation of Ocrl and its role in human disease progression is needed and 



















I would like to express the deepest appreciation to my supervisor, Dr. Brian E. 
Staveley, who has the attitude and the substance of a genius. Without his guidance and 
persistent help this dissertation would not have been possible. I would like to thank my 
supervisory committee, Dr. Dawn Marshall and Dr. Curtis French, for providing 
positive criticism and feedback throughout my project.  
I am extremely grateful to the Memorial University of Newfoundland School of 
Graduate Studies Baseline Funding. Graduate Assistantship, Department of Biology, 
Memorial University of Newfoundland. Funding of Staveley Research group by 
National Science and Engineering Council of Canada NSERC Discovery Grant 
Program (individual) “Signalling mechanisms integrating cell survival, organism 
growth and stress-resistance in Drosophila” Parkinson Society of Newfoundland and 
Labrador “Novel aspects of intracellular trafficking in Drosophila models of Parkinson 
Disease” Memorial University of Newfoundland Seed, Bridge and Multidisciplinary 
Fund. 
I would like to thank former and current Staveley lab members for providing a positive 
a positive and encouraging environment. Special thanks must be extended to Dr. 
Jennifer Slade and Azra Hasan for their experimental aid and edits and feedback 
v 
 
throughout the project. Finally, I wish to thank my parents and family, who have 



























Table of Contents 
Abstract…………………………………………………………………………………………...ii 
Acknowledgment……………………………………………………………..….……………….iv 
Table of Contents…………………………………………………………………………...…….vi 
List of Figures………………………………………………………………………….….…….viii 
List of Tables…………………………………………………………………………..…...…......x 
List of Abbreviations…………………………………………………………………...………..xii 
Introduction…………………………………………………………………………………..…....1 
Parkinson Disease……………………………………………………………….…….......1 
PD Gene Loci……………………………………………………………………………...2 
Drosophila melanogaster as a Model Organism………………...……………...………...5 
UAS-GAL4 System…………………………..……………………………………….…....8 
RNA Interference (RNAi) and its function………………………………………………11 
Gene of Interest……………………………………………………………..……..……..11 
The cellular roles of Ocrl…………………………………………………………………14 
Goals and Objectives ……………………………………………………………………17 
Materials and Methods…………………………………………………………………………...18 
Bioinformatics assessment……………………………………………………...………..18 
Drosophila melanogaster Culturing and Crosses……………….………………...…..…19 
Media and Culture………………………………………………………………………..22 





Bioinformatics Analysis ……….…………………………………..………………….…26 
Eye Analysis ……………………………………………………….……………………33 
Effects of the Overexpression of Ocrl upon Longevity and Climbing Ability….………40 
Effects of the Inhibition of Ocrl upon Longevity and Climbing Ability ………………..48 






















List of Figures 
Figure 1: Scanning electron micrograph of Drosophila melanogaster eye of the genotype GMR-
GAL4; UAS-lacZ………………………………………………………………………………..…7 
Figure2: UAS-Gal4 system in Drosophila melanogaster…………………….….………....…..…9 
Figure 3: The Alignment of protein encoded by Drosophila melanogaster Ocrl with human Ocrl 
protein………………………………………………………………………………….………...28 
Figure 4: Pairwise Sequence Alignment of Ocrl domains…………………………………...…30  
Figure 5: Alignment of human Ocrl protein with similar protein from selected vertebrates and 
invertebrates……………………………………………………………………..……………….32 
Figure 6: Compound eye of Drosophila melanogaster with altered Ocrl expression visualized by 
scanning electron microscopy.……………….………………………………………..…………35 
Figure 7: Biometric analysis of the Drosophila melanogaster eye under the influence of eye 
specific expression with the inhibition of Ocrl…………………………………………………..36 
Figure 8: Biometric analysis of the compound eye under the influence of eye specific expression 
with the overexpression of Ocrl………………………..………………………………...………38 
Figure 9: Overexpression of Ocrl in the motor neurons causes a significant decrease in climbing 
ability of flies………………………...………………………………………………………..….42 
Figure 10: Overexpression of Ocrl in the dopaminergic and serotonergic neurons does not cause 
a significant decrease in climbing ability of flies…………………….………………………….43 
Figure 11: Overexpression of Ocrl in the dopaminergic neurons does not cause a significant 
decrease in climbing ability of flies…………………...…………………………………………44 
Figure 12: Overexpression of Ocrl in the motor neurons causes a decrease in longevity of 
flies…………………………………………………………………………………………….…45 
Figure 13: Overexpression of Ocrl in the dopaminergic and serotonergic neurons causes a 
decrease in longevity of flies………………………………………………...………….……….46 
Figure 14: Overexpression of Ocrl in the dopaminergic neurons causes a significant increase in 
longevity of flies………………………………………………………………………………....47 
Figure 15: Inhibition of Ocrl in motor neurons causes a significant decrease in climbing ability of 
flies……………………………...……………………………….……………………………….49 
Figure 16: Inhibition of Ocrl in dopaminergic neurons causes a significant decrease in climbing 
ability of flies………………………………...…………………………………………….……..50 
ix 
 
Figure 17: Inhibition of Ocrl in dopaminergic and serotonergic neurons causes a significant 
decrease in climbing ability of flies………………………………………………………….…..51 
Figure 18: Inhibition of Ocrl in the motor neurons causes a decrease in longevity of flies…….52 
Figure 19: Inhibition of Ocrl in the dopaminergic neuron does not cause a significant decrease in 
longevity…………………………………………………………………………………………53 
Figure 20: Inhibition of Ocrl in the dopaminergic and serotonergic neurons does not cause a 
significant decrease in longevity of flies……………………………………………..………….54 
Figure 21: The overexpression of Ocrl along with park expression in the ddc-Gal4-expressing 
neurons……………………………………………………………………..…………………….56 
Figure 22: The inhibition of Ocrl along with park expression in the ddc-Gal4-expressing 
neurons…………………………………………………………………………………….…..…58 
Figure 23: The inhibition of Ocrl along with park expression in the ddc-Gal4-expressing neurons 
does not cause a significant decrease in longevity………………………………..……..….……61 
Figure 24: The overexpression of Ocrl along with park expression in the ddc-Gal4-expressing 
neurons does not cause a significant decrease in longevity………………………………..…….62 
Figure 25: The inhibition of Ocrl along with park expression in the ddc-Gal4-expressing neurons 
had no significant difference in climbing ability of flies when compared to the 
control…………………………………………………………………………………………....64 
Figure 26: The overexpression of Ocrl along with park expression in the ddc-Gal4-expressing 

















List of Tables 
Table 1: Gene loci implicated in Parkinson Disease………………………………………….…..4 
Table 2: Genotypes of all stocks used to characterize Ocrl in this study…………….….……...21 
Table 3: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
inhibited in the compound eye………………...…………………………………………………37 
Table 4: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
overexpressed…………………………………………………………………………………….39 
Table 5: Comparison of climbing ability flies with overexpression of Ocrl in the motor neurons 
using Log-rank test……………………………………………………………………………....42 
Table 6: Comparison of climbing ability of flies with overexpression of Ocrl in the 
dopaminergic and serotonergic neurons using Log-rank test…………………………….……...43 
Table 7: Comparison of climbing ability of flies with overexpression of Ocrl in the 
dopaminergic neurons using Log-rank test………………………………………………………44 
Table 8: Comparison of survival of flies with overexpression of Ocrl in the motor neurons using 
Log-rank test…………………………...………………………………………………….……..45 
Table 9:  Comparison of survival of flies with overexpression of Ocrl in the dopaminergic and 
serotonergic neurons using Log-rank test……………………………….……………………….46 
Table 10: Comparison of survival of flies with overexpression of Ocrl in the dopaminergic 
neurons using Log-rank test……………………………………………………………………...47 
Table 11: Comparison of climbing ability of flies with inhibition of Ocrl in the motor neurons 
using Log-rank test……………………….……………………………………………………...44 
Table 12: Comparison of climbing ability of flies with inhibition of Ocrl in the dopaminergic 
neurons using Log-rank test………………………………………………………………….…..50 
Table 13: Comparison of climbing ability of flies with inhibition of Ocrl in the dopaminergic 
and serotonergic neurons using Log-rank test…………………………………………………...51 
Table 14: Comparison of survival of flies with inhibition of Ocrl in the motor neurons using 
Log-rank test…………………………………………………….……………………………….52 
Table 15: Comparison of survival of flies with inhibition of Ocrl in the dopaminergic neurons 
using Log-rank test………………………………………………………………………………53 
Table 16: Comparison of survival of flies with inhibition of Ocrl in the dopaminergic and 
serotonergic neurons using Log-rank test………………………………………………………..54 
Table 17: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
overexpressed and park is inhibited in the developing eye……………………………………..57 
 
Table 18: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
inhibited in the compound eye…………………………………………………………………..59 
xi 
 
Table 19: Comparison of longevity of flies with inhibition of Ocrl along with park expression in 
the ddc-Gal4-expressing neurons by Log-rank test……………………………………………...61 
Table 20: Comparison of longevity of flies with overexpression of Ocrl along with park 
expression in the ddc-Gal4-expressing neurons by Log-rank test…………………………….…62 
Table 21: Comparison of climbing ability of flies with inhibition of Ocrl along with park 
expression in the ddc-Gal4-expressing neurons by Log-rank test………..….…………………..64 
Table 22: Comparison of climbing ability of flies with overexpression of Ocrl along with park 


























List of Abbreviations 
 
AD – Autosomal Dominant 
BLAST – Basic Local Alignment Search Tool 
tBLASTn – Translated Nucleotide Basic Local Alignment Search Tool 
Cm – Centimetre 
CI – Confidence Interval 
CNS – Central Nervous System 
CO2 – Carbon dioxide 
D. melanogaster – Drosophila melanogaster 
DA – Dopaminergic 
ddc – dopa decarboxylase 
g/L – grams per liter 
g/ml – grams per milliliter 
GMR – Glass Multiple Reporter 
GOF – Gain-Of-Function 
INPP5B – inositol polyphosphate-5-phosphatase B 
lacZ – β-galactosidase 
LBs – Lewy Bodies 
PD – Parkinson Disease 
ml/L – milliliters per liter 
ml – milliliters 
mRNA – messenger RNA 
N/A – Not Applicable 
NCBI – National Center for Biotechnology Information 
Ocrl – Oculocerebrorenal syndrome of Lowe 
PINK1 – PTEN-induced putative kinase 1 
RISC – RNA-Induced Silencing Complex 
xiii 
 
RNA – Ribonucleic acid 
RNAi – RNA interference 
ROS –  Reactive Oxygen Species 
SE – Standard Error 
SEM – Standard Error of the Mean 
SNc – substantial nigra pars compacta 
TH – Tyrosine Hydroxylase 
°C – Degree Celsius 
α-synuclein – alpha-synuclein 















Parkinson Disease (PD) is the most common movement disorder and the second most 
common neurodegenerative disease, affecting 1 to 2% of all individuals worldwide over the age 
of 60 years (Lew, 2007).  This prevalence in the 80-plus age category is as high as 4% (Tysnes & 
Storstein, 2017). PD has characteristics including resting tremor, slowness of movement, rigidity 
and postural reflex impairment. Other manifestations include loss of memory and depression 
(Wirdefeldt et al., 2011). These symptoms are caused by the degeneration of dopaminergic neurons 
of the substantia nigra pars compacta (SNc) in the midbrain of patients (Dauer & Przedborski, 
2003) and often characterized by the presence of intraneuronal proteinaceous inclusions termed 
Lewy Bodies (LBs) and Lewy Neurites (LN) in the limbic structure and cerebral cortex which may 
cause dementia in 25 to 40% of PD patients (De Lau & Breteler, 2006). Dementia is associated 
with a decrease in the life quality of patients and increased mortality.  
Many genetic and environmental factors for the progression of PD have been identified. 
Most cases of PD are considered to be sporadic with late-onset and no known cause (Cauchi and 
Heuvel, 2006; Lu and Vogel, 2009). Several environmental factors, such as chemical exposure, 
brain trauma, obesity, age, and diabetes have been well identified with the onset of PD (Vanitallie, 
2008). The investigation of the genes associated with the familial forms of PD (FPD) has provided 
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an opportunity to study the mechanisms in model organisms of both FPD and sporadic PD 
pathogenesis (De Lau & Breteler, 2006). Although some therapies have been investigated for PD, 
all are focusing on reducing symptoms and there is no cure for advanced PD yet. The use of model 
organisms, such as Drosophila melanogaster for the study of disease progression is an essential 
step in understanding the molecular mechanism behind disease pathology in patients. 
PD Gene Loci 
To date, 20 Parkinson-associated (PARK) gene loci have been examined through a 
combination of sequence analysis, segregation and linkage; though several of these gene loci 
require independent study confirmation (Table 1). α-synuclein was the first of the genes identified 
in association with the rare familial forms of PD (Polymeropoulos et al., 1997; Kruger et al., 1998). 
Among these gene loci, several have been cloned including α-synuclein/PARK1 (Polymeropoulos 
et al., 1997), Parkin/PARK2 (Kitada et al., 1998), Ubiquitin C-terminal hydrolase1 (Uchl-
1)/PARK5 (Leroy et al., 1998), Phosphatase and tensin homologue [PTEN] induced kinase 
(Pink1)/PARK6 (Valente et al., 2004), DJ-1/PARK7 (Bonifati et al., 2003) and leucine-rich repeat 
kinase 2 (LRRK2)/PARK8 (Zimprich et al., 2004). Among the genes found, Leucine-rich repeat 
kinase 2 or LRRK2 and α-synuclein/ PARK1 known as autosomal dominant alleles (AD) or gain-
of-function form of PD genes, whereas the rest are autosomal recessive alleles (AR) or loss-of-
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function mutant genes (Staveley, 2012). The pathological mechanism helps us to better understand 
the sporadic causes of PD and the underlying pathological mechanism of FPD. 
 A recent genome wide association study (GWAS) research article described several new 
PD-related genetic loci that clustered into two main groups (Jansen et al., 2017). The first one 
related to LRRK2 and FBXO7 gene, and the second one associated with SNCA, PINK1, PARK2, 
PARK7, ATP13A2, and GBA. Ocrl is one of the validated genes which shows a strong interaction 













Table 1: Gene loci implicated in Parkinson Disease 





4q21 Dominant Presynaptic protein, 
Lewy body, lipid 
dynamics 
PARK2 Parkin 6q26 Recessive  Ubiquitin E3 ligase, 
mitophagy 
PARK3 Unknown 2p13 Dominant  Unknown 
PARK5 UCH-L1 4p14 Dominant Ubiquitin C-
terminal hydrolase 
PARK6 PINK1 1p36 Recessive Mitochondrial 
kinase 
PARK7 DJ-1 1p36 Recessive Oxidative stress 
PARK8 LRRK2 12q12 Dominant Kinase signaling, 
cytoskeletal 
dynamics 
PARK9 ATPA13A2 1p36 Recessive Unknown 
PARK10 Unknown 1p32 Dominant Unknown 
PARK11 GIGYF2 2q36-q37 Dominant IGF-1 signaling 
PARK12 Unknown Xq21 X-linked Unknown 
PARK13 HTRA2 2p13 Dominant Mitochondrial 
serine protease 
PARK14 PLA2G6 22q13 Recessive Phospholipase 
enzyme 
PARK15 FBXO7 22q12-q13 Recessive  Ubiquitin E3 ligase 
PARK16 Unknown 1q32 Unknown Unknown 
PARK17 VPS35 16q11 Dominant Unknown 
PARK18 EIF4G1 3q27 Dominant Unknown 
PARK19A/B DNAJC6 1P32 Recessive Unknown 
PARK20 SYNJ1 21q22 Recessive Unknown 
1. A locus refers to the location on the chromosome where the gene is found.  
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Drosophila melanogaster as a model organism 
 
A wealthy range of experimental methods have been applied to explore the different 
functions of human disease genes. Human disease gene expression in the “common fruit fly” 
Drosophila melanogaster, is an approach that has drawn much attention for modeling 
neurodegenerative diseases. D. melanogaster has been used as a model organism due to its small 
size, rapid life cycle with numerous offspring in a single cross and cheap culturing requirements. 
More importantly, it has been estimated that nearly 75% of human disease-related genes have 
functional orthologues in the fruit fly (Reiter et al., 2001) and it was the first complex organism 
whose genome was sequenced (Adams et al., 2000). Genetic redundancies (existence of multiple 
genes in the genome of an organism) is lower in D. melanogaster, which in terms of the genome 
of this species is simple compared to mammalian counterparts (Bier, 2005). Although it has the 
simpler nervous system in comparison to human, D. melanogaster possess a compartmentalized 
nervous system that can be manipulated genetically (Brand et al., 1994).  The brain, neurons and 
glia, are found in both D. melanogaster and humans. The adult D. melanogaster nervous system 
has about one-millionth as many neurons as human has (O’Kane et al., 2011) and it is organized 
into various specialized areas that are used for the processing of olfactory and visual information 
and the integration of learning and memory (Wolf and Herbelein, 2003; Cauchi and Heuvel, 2006; 
Hardaway, 2010). The presence of 4 lobes and about 100 billion neurons in the human nervous 
system is what makes a human brain much more complicated than flies. However, the brain of D. 
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melanogaster consists of three lobes (protocerebrum, deutocerebrum and the tritocerebrum) that 
have been shown to be homologous to the forebrain, midbrain and hindbrain regions of vertebrates. 
Although there is a difference in the complexity of human and D. melanogaster nervous systems, 
they both share a common functional and molecular characteristic (O’Kane et al., 2011).  These 
features make the D. melanogaster an ideal organism to investigate the complex pathways in 
biomedical researches. The presence of homologous PD genes and a high-level of functional 
preservation has attracted significant attention to the use of D. melanogaster as a PD experimental 
model organism. 
It is possible to measure the neurodegeneration in the D. melanogaster eye, due to its 
associations with neurons. The adult Drosophila eye comprises a repeated array of approximately 
750 to 800 multicellular subunits known as ommatidia for light sensing purpose (Figure 1). Each 
ommatidium made up of eight photoreceptors, which are photosensitive neurons. This means there 
is a large number, over 6000, of neurons in the eye of D. melanogaster (Frankfort et al., 2002). 
Neuron specific expression can be achieved in the eye cells using a driver, GMR-GAL4 (Freeman, 
1997). The differentiation of the specialized cells that will become photoreceptors begins in the 
eye imaginal disc with clusters of differentiating neurons.  
Modifier screens combine the benefits of forward and reverse genetic screens which 
require easily accessible phenotypes and sensitive to genetic modifications (Lenz et al., 2013). In 
the neurodegenerative diseases, the expression of disease-linked gene product is targeted to the fly 
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eye. This might lead to a rough eye phenotype caused by degeneration of eye specific cells. The 
number of interommatidial bristles and ommatidia can be analyzed as changes in the eye structure 
and be considered as a neurodegeneration marker. In addition, the developing D. melanogaster 
eye is a desirable system for the study of cellular mechanisms, including communication between 
cells, signaling methods and cell fate specification (Thomas and Wassarman, 1999). Previous work 
from different laboratories (Botella et al., 2009) including our laboratory, has found that D. 
melanogaster is a useful PD research model organism. 
 
    
Figure 1. Scanning electron micrograph of Drosophila melanogaster eye of the genotype 
GMR-GAL4; UAS-lacZ. The presence of ommatidia and interommatidial bristles are evident in 






Over the past decade the adoption of the GAL4 system by the Drosophila field has resulted 
in a wide range of tools with which the researcher can drive transgene expression in a specific 
pattern. The GAL4 system depends on two components: (1) GAL4, a transcriptional activator from 
yeast, which is expressed in a tissue-specific manner and (2) a transgene under the control of the 
upstream activation sequence that is bound by GAL4 (UAS). In a simple genetic cross, the two 
components are brought together. In the progeny of the cross, the transgene is transcribed only in 
those cells or tissues expressing the GAL4 protein. Recent modifications of the GAL4 system have 
improved the control of both the initiation and the restriction of transgene expression.  
Different types of tissue-specific GAL4 fly lines are used in PD modeling, including the 
motor neuron-specific promoter; D42, dopaminergic and serotonergic neurons-specific promoter; 
dopa decarboxylase (ddc), the dopaminergic neuron-specific promoter; tyrosine hydroxylase 
(TH), and the eye-specific promoter; glass multiple reporter (GMR) (Feany & Bender, 
2000; Boto et al., 2014). The reason for selecting these tissue-specific GAL4s is that PD patients 
are weak due to disease of motor neurons, dopaminergic and serotonergic neurons. The UAS-GAL4 






Figure 2: UAS-Gal4 system in D. melanogaster. Gal4 drives expression of UAS-target gene in 















RNA Interference (RNAi) and its function 
RNA Interference (RNAi) is one of the essential techniques in modern biology, enabling 
us to understand the effects of the loss of function of particular genes, which in D. melanogaster 
can be coupled with the UAS/GAL4 system (Dietzl et al., 2007). RNAi is a regulatory method 
which destroys the activity of a selected endogenous gene. In the cytoplasm, a ribonuclease 
enzyme called Dicer cleaves long double-stranded RNA (dsRNA) molecules into an short, 
interfering RNA (siRNA). Such fragments then unwind into single -stranded short interfering RNA 
which are then integrated into complexes called RNA-induced silencing complexes (RISCs). RISC 
has a nuclease component called either Argonaute or Slicer which degrades the mRNA depending 
upon the exact complementarity of the short interfering RNA. Degradation of the mRNA generated 
from a gene leads to the silenced expression of that gene. Through the loss of gene function, its 








Gene of interest 
The inositol polyphosphate 5-phosphatases (5-phosphatases) are a family of dependant 
phosphoesterases that dephosphorylate the 5 positions of the inositol ring selectively from the 
inositol ring of different second messengers, including the water-soluble inositol phosphates 
Ins(1,4,5)P3 and Ins(1,3,4,5)P4, and the lipid-bound PtdIns-derived molecules PtdIns(4,5)P2, 
PtdIns(3,4,5)P3, and PtdIns (3,5) P2 (Astle et al., 2006). The human genome encodes 10 inositol 
5-phosphatases. Mutations in one of them, Ocrl, leads to Oculocerebrorenal syndrome of Lowe, 
presents in eukaryotic cells and is located on the X chromosome in human.  
 Human Ocrl encodes 901 amino acids and contains a Pleckstrin homology (PH)-like 
domain, INPP5c domain and a Rho-GAP domain. PH-like domains have different functions, but 
in general are involved in targeting proteins to the appropriate cellular location or in the interaction 
with a binding partner (Noakes et al., 2011). Catalytic inositol polyphosphate 5-phosphatase 
(INPP5c) domain belongs to a family of Mg2+-dependent inositol polyphosphate 5-phosphatases, 
which hydrolyze the 5-phosphate from the inositol ring of various 5-position phosphorylated 
phosphoinositides (PIs) and inositol phosphates (IPs), and to the large EEP 
(exonuclease/endonuclease/phosphatase) superfamily that share a common catalytic mechanism 
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of cleaving phosphodiester bonds (Schmid et al., 2004; Zhang et al., 1995) and a catalytically 
inactive Rho GTPase activating (RhoGAP) domain that mediate the interactions with membrane-
associated proteins such as Rab GTPases, IPIP27A/B, and APPL. 
Ocrl is involved in the various biological process including ciliogenesis, intracellular 
trafficking, clathrin-mediated endocytosis, actin cytoskeleton regulation, and cytokinesis (De 
Matteris et al.,2004). It is orthologous to several human genes including INPP5B (inositol 
polyphosphate-5-phosphatase B) which may compensate the loss of Ocrl (Luo et al.,2013). By 
contrast, D. melanogaster expresses only a single homologue of Ocrl (Ben et al., 2012), and may 
therefore be a valuable model for understanding the functions of Ocrl in complex tissues in vivo.  
Mutations in Ocrl are believed to cause cellular deficiency in endocytosis (Nandez et al., 
2014), endosomal trafficking (Billcliff et al., 2016; Cauvin et al., 2016), actin cytoskeletal 
rearrangements (Grieve et al., 2011, Coon et al., 2009), autophagy (De Leo et al., 2016), 
cytokinesis (Dambournet et al., 2011), and primary cilia signaling (Mehta et al., 2014). Human 
ortholog(s) of this gene is implicated in Dent disease and oculocerebrorenal syndrome. 
Oculocerebrorenal syndrome is an X‑linked disease characterized by congenital cataracts. Dent 
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disease 2, is a milder disorder that results in Fanconi's renal syndrome. (Mehta et., 2014). In vitro, 
the function of INPP5B is significantly decreased in most cells obtained from patients with Ocrl 
mutations in comparison to healthy controls (Hichri et al., 2011). 28 loci for Parkinson's disease 
were identified and replicated by a recent large-scale meta-analysis of genome-wide association 
data in Europe, including six new risk loci (SIPA1L2, INPP5B, MIR4697, GCH1, VPS13C, and 
DDRGK1) (Nalls et al., 2014). Therefore, Ocrl may show previously unknown features of 
Parkinson Disease. 
The cellular roles of Ocrl 
The endolysosomal system consists of complex, highly dynamic membrane‐enclosed 
tubular‐vesicular structures. They enable nutritional intake through endocytosis from a cell's 
microenvironment, neutralise pathogenic materials through phagocytosis, promote cellular 
proteostasis via autophagy, and maintain overall cellular homeostasis (Repnik et al., 2013). Below 
I present some of the endolysosomal compartments with which Ocrl is associated and the 
implicated biological functions. 
Plasma membrane 
Ocrl is targeted to the plasma membrane by Rac1, a member of the Rho‐GTPase family 
that regulates actin cytoskeleton dynamics, transcriptional regulation and progression of the cell 
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cycle (Wang et al., 2003). Epidermal growth factor signaling lead to the association of Rac1 which 
activates the gene expression of Ocrl (Fauchere et al., 2003). Ocrl controls PI(4,5)P2 levels at the 
plasma membrane, which in fact increase in cells lacking Ocrl. This increase in PI(4,5)P2 levels 
at the plasma membrane leads to formation of actin comets (Nandez et al., 2014), and decreases 
cell adhesion and migration. By interaction with APPL1 and Rab5, Ocrl associates with closing 
phagosomes at the plasma membrane of macrophages. Within increase in the levels of PI(4,5)P2, 
Ocrl regulates the sealing of phagosomes by reducing PI(4,5)P2 levels to allow the disassembly 
of actin and enable the complete closure of phagosomes. 
Clathrin-coated vesicles and early endosomes 
Ocrl is recruited to clathrin‑coated vesicles through its interaction with clathrin and the 
clathrin adaptor AP2. It acts as a switch in clathrin‑coated vesicles, where it determines the 
transition from a stage with high PI(4,5)P2 levels in which PI(4,5)P2‑binding components of the 
clathrin and actin machinery to a stage with low PI(4,5)P2 levels in which clathrin uncoating 




Ocrl also interacts with early endosomes where it acts to maintain low levels of PI(4,5)P2 
for proper endocytic trafficking (Choudhury et al., 2005). Ocrl deficiency leads to an increase in 
PI(4,5)P2 levels in early endosomes, resulting in PI(4,5)P2 and stimulation of actin 
polymerization. This uncontrolled actin polymerization impedes the trafficking of different classes 
of receptors by early endosomes (Vicinanza et al., 2005). Some receptors that are affected by 
impaired trafficking include those destined for the Golgi complex, those destined for degradation, 
such as epidermal growth factor; and those passing through early endosomes for rapid recycling 
back into the plasma membrane, such as megalin. One of the pathogenetic mechanisms linking 
Ocrl dysfunction with Fanconi syndrome may be the trapping of megalin in early endosomes. 
Lysosomes  
Ocrl can also localize on lysosomes. Through endosome–lysosome fusion, lysosomes 
receive cargo from late endosomes (Saftig et., 2009). By mounting a lysosome cargo response, 
cells ensure optimum lipid composition of the lysosomal membranes for maintaining proper fusion 
events. PI(4,5)P2 synthesis plays an important role for the recycling of components of the fusion 
machinery, such as the autophagosomal SNARE protein syntaxin 17. However, lysosomal levels 
of PI(4,5)P2 need to be controlled throughly. In the absence of Ocrl, the unregulated accumulation 
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of lysosomal PI(4,5)P2 affects autophagosome–lysosome fusion by inhibiting the lysosomal 
calcium channel TRPML1 (Zhang et al., 2012). TRPML1 is activated by PI(3,5)P2, which induces 
release of calcium to allow proper fusion of autophagosome–lysosome. 
Endolysosomal system dysfunction 
Recent developments in PD genetics point that most PD-linked genes (Table 1) and 
established pathomechanisms are correlated with the endolysosomal system in one way or another, 
and strongly suggest this pathway as the primary master regulator of PD pathogenesis.  
(Vidyadhara et al., 2019). Due to the wide range of interactions that Ocrl can engage in 
endolysosomal system, the connections between malfunctions of Ocrl and PD is not surprisingly. 








Goals and Objectives 
In this research work, I determined the effect of altering Ocrl gene in D. melanogaster in 
order to make a novel model of Parkinson disease. This research concentrates on the three goals: 
1) Performing the bioinformatics analysis of Ocrl to analyze the homology in different species 
in order to evaluate the possibility of using Drosophila as a model for PD.  
2) To examine whether the inhibition and overexpression of Ocrl in D. melanogaster may 
affect lifespan, climbing ability and the compound eye over time.  
3) To examine if inhibition and overexpression of Ocrl expression may affect lifespan and 
climbing ability and the compound eye over time in the previously established park loss-









Materials and Methods 
Bioinformatics assessment 
Identification of the Drosophila melanogaster homologue of Ocrl  
Different bioinformatics tools were carried out to understand the potential biological 
function of the Drosophila melanogaster homologue of the human gene Ocrl. The 
nucleotide sequence of the human PD candidate gene Ocrl (NC_000023.11), the 
homologueous gene of Drosophila melanogaster Ocrl (NC_004354.4) and other 
species genes were identified using the National Centre for Biotechnology Information’s (NCBI) 
database (http://www.ncbi.nlm.nih.gov/).  and fly Base website (https://flybase.org/). To 
identify the Drosophila melanogaster homologue of human Ocrl, 
a translated nucleotide database using protein query search (tBLASTn) was performed using the 
Basic Local Alignment Search Tool (BLAST) (www.ncbi.blast.com). For multiple 
sequence alignment, Cluster Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) and for 
two sequences, Pairwise Sequence Alignment (https://www.ebi.ac.uk/Tools/psa/), were 
applied to indicate identity and similarity of protein sequences. Conserved domains in the Ocrl 
protein sequences of both vertebrate and invertebrate species were identified using the Conserved 
Domain Database (CDD) tools of NCBI (https://www.ncbi.nlm.nih.gov/cdd) and domain 




Drosophila melanogaster Culturing and Crosses 
The stocks used to direct the overexpression of Ocrl, y1 P{EPgy2}OcrlEY15890 w67c23 
(designated as UAS-OcrlEY) with the stock number of 21170, and the stocks utilized to direct the 
RNA interference of Ocrl, P{TRiP.HMS01201}attP2/TM3, Sb1 (designed as UAS-Ocrl-RNAiHMS) 
with stock number of 34722,  were obtained from the Bloomington Drosophila Stock Center, 
Indiana University, Bloomington, USA. The other stocks utilized to direct the RNA interference 
of Ocrl, w1118; P{GD11016}v34649 (designed as UAS-Ocrl-RNAiGD) with stock number of 34649, 
and P{KK101922}VIE-260B (designed as UAS-Ocrl-RNAiKK) with stock number of 110796, were 
obtained from the Vienna Drosophila Resource Center, Austria. Detailed information about these 
stocks are available from http://www.flybase.org. 
The dopa decarboxylase (ddc)-Gal4 fly line (BDSC7010) was provided by Dr. J. Hirsh 
(University of Virginia).  The tyrosine hydroxylase (TH)-Gal4, (BDSC:8848), glass multiple 
reporter (GMR)-Gal4 (BDSC:1104), D42-Gal4 (BDSC:8816), and control line UAS-lacZ 
(BDSC:1776) were obtained from the Bloomington Drosophila Stock Centre at Indiana 
University. In Drosophila, lacZ is often used in enhancer trap screens to identify genes that are 
expressed in a tissue-specific manner or as a reporter to identify tissue-specific regulatory regions.  
The recombinant lines GMR-GAL4; UAS-parkRNAi and ddc-GAL4; UAS-parkRNAi were 
prepared by Dr. Brian E. Staveley. Table 2 shows the expression patterns of fly lines used in this 
analysis and the place of insertion. 
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To maintain consistency throughout the entire experiment, only male progeny was selected 
to determine Ocrl gene effect on flies. In addition, reproductive stress is notable in females as far 
as ageing is concerned and isolating virgin females could make this experiment much more time-





















Table 2: Genotypes of all stocks used to characterize Ocrl in this study. 
Genotypes Abbreviation Expression Balancer 
Control line:  
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Media and culture 
Fly stocks were cultured on a standard media. This media is a standard cornmeal-yeast-
molasses-agar medium (65 g/L cornmeal, 15 g/L nutritional yeast extract, 5.5 g/L agar, 50 ml/L 
fancy grade molasses in water supplement with 0.1 g/mL methyl paraben in ethanol and 2.5 mL 
of propionic acid. Flies were maintained at 25 ̊ C. To prevent the growth of mold, the medium used 
was treated with 2.5 ml/L propionic acid and 5 mL of 10% methyl paraben in ethanol. The vials 
were then stored at 4° C to 6° C until they were used. Drosophila stocks were maintained on this 
medium for 2 to 3 weeks and were then transferred to new media. The medium was prepared by 
Dr. Brian E. Staveley approximately twice a month. Crosses were completed by first isolating 
virgin females of the maternal genotypes every 8 to 12 hours. Males were isolated 1 day before 
the cross was prepared. When enough females had been collected, 3 to 5 females of the appropriate 
maternal genotype were placed along with 2 to 3 males of the paternal genotype. Flies were then 
allowed to breed. In order to increase the productivity of the breeding the flies were placed onto 
new media 3 separate times every 2 to 3 days. The parental flies were then discarded and the male 
progeny of the critical class were collected once enclosure occurs. 
Analysis of the Compound Eye 
The compound eye of Drosophila was taken to examine the effects of gene manipulation 
on ommatidia and interommatidial bristle numbers. Male flies of each individual cross were 
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collected in groups of up to 20 per vial after eclosion and matured for 3 to 5 days on standard 
media. Flies were preserved at -80 °C before being mounted on metal studs with the left eye facing 
upwards and desiccated overnight. Prepared flies were gold coated before photographs were taken 
at 150X magnification using a Hitachi S-570 Scanning Electron Microscope, located at the 
Bruneau Centre for Innovation and Research (IIC). At least 10 eye images per genotype were 
analyzed by the National Institute of Health (NIH) ImageJ software 
(https://imagej.nih.gov/ij/download.html) and GraphPad Prism version 8.0.0 was used for 
performing biometric assay Unpaired t-tests were used to determine significance. Results were 
deemed statistically significant when p values were less than or equal to 0.05. 
Longevity assay 
An analysis of survival of D. melanogaster was carried out to examine the lifespan of 
affected flies and the comparison to control flies. To avoid crowding during development, crosses 
were made in 5 vials, each containing 2 to 4 females and 2 to 4 males of each genotype.  Male 
progeny of the critical class was collected under gaseous carbon dioxide (CO2) every 24 hours 
upon eclosion and maintained at 25 °C (≤20 individuals initially per vial to avoid overcrowding) 
until a sample size of 300 individuals for each cross has been collected (10 flies per vial). Flies 
were scored for viability every 2 days and transferred to fresh medium without anesthesia. Flies 
were considered dead when there was no movement during agitation (Staveley et al., 1990). Data 
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was analyzed using the software Graphpad 8.0.0 Prism software (Slade and Staveley, 2015). 
Survival curves were compared using a log-rank tests where a p value less than or equal to 0.05 
with Bonferroni correction was considered significant. 
Locomotor analysis 
Fifty adult males for each genotype were isolated under gaseous CO2 on the day of eclosure 
and maintained at 25°C on standard cornmeal-yeast-molasses-agar media in groups of 10 
individuals and transferred to new food twice a week throughout the experiment. Beginning at day 
2 post eclosion, and at regular seven day intervals afterward, flies were scored for climbing ability 
as described by Todd and Staveley (2004), using an apparatus consisting of a 30 cm long clear 
glass tube with a diameter of 1.5 cm. The tube was divided into five 2 cm sections along with a 
buffer zone. Transferred without anesthesia, each vial was assayed ten times and flies were given 
10 seconds to see which sections they had reached. Flies were scored 10 times per trial. A climbing 
index was calculated to determine climbing ability, using the formula: Climbing Index = (nm/N) 
where n is the total number of flies at a given level, m is the score for the level (1-5) and N is the 
total number of flies climbed (Todd and Staveley, 2004).  Data was analyzed using the software 
GraphPad 8.0.0 Prism. The slope of curves with non-overlapping 95% confidence intervals was 
used to analyze the graphs of 5-climbing index as a function of time in days for each genotype. 
The slope for each graph shows the rate of decline in climbing ability and the Y-intercept shows 
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the initial climbing ability and both of these parameters are calculated for each curve (Merzetti and 
Staveley, 2015). A regression curve was applied with a 95 % confidence interval to analyze the 





















The amino acid sequence of the human Ocrl protein (Q_01968) of 
901 amino acids was obtained from the NCBI website. A tBLASTn search of the Drosophila 
melanogaster genome was conducted and gene Ocrl (NP_001259153.1) was 
identified as the protein sequence most similar to human Ocrl, with 850 amino acids. These two 
sequences were aligned using, Pairwise Sequence Alignment and Clustal Omega multiple 
sequence alignment to identify regions and percentage of similarity. The overall 32.9% identity 
and 48.0% similarity between the human and Drosophila melanogaster was identified (Figure 3). 
The conserved Domain Database of NCBI and Pfam were used for the identification of PH-like 
domain, INPP5c domain and the RhoGAP domain. Pairwise Sequence Alignment of Ocrl domains 
in human and Drosophila showed PH-like super family associated domain (identity-43.6%; 
similarity-53.6%), INPP5c domain (identity-41.1%; similarity-55.3%), RhoGAP domain 
(identity-32.7%; similarity- 47.7%) (Figure 4). 
The Ocrl protein is conserved between vertebrates and invertebrates 
 The multiple alignments of vertebrate and invertebrate versions of the Ocrl protein was 
conducted using sequences from D. melanogaster (NP_001259153.1). When comparing vertebrate 
and invertebrate species, the Ocrl proteins show some similarities in residues among the species. 
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The alignment showed common Pleckstrin homology (PH) domain, inositol polyphosphate 5-
phosphatase (INPP5c) domain and the RhoGAP domain.  
A BLASTn search of NCBI identified potentially homologous versions of vertebrate and 
invertebrate Ocrl-related-protein, including Homo sapiens (NP_001337156.1), Zebrafish 
uhrf1bp1l Danio rerio (XP_017206941.1) and frog uhrf1bp1l  Xenopus laevis (accession number 
XP_002939536.2), buff-tailed bumblebee (Bombus terrestris (XP_012169971.1), honey bee 
(Aedes aegypti (XP_021709736.1) and D. melanogaster (NP_001259153.1) (Figure 3) were 
aligned by Clustal Omega multiple sequence alignment to identify amino acids similarity. These 
species share similarity over their entire length, such as conserved segments. The multiple 
sequence alignment of vertebrate and invertebrate Ocrl proteins was performed using the CD-
search tool of NCBI Conserved Domain Database Search and Pfam for identification of conserved 
and functional domains; the result indicated that INPP5c and the RhoGAP domains were all highly 





Drosophila      -------------------MDTLSEAVANG------------TATAATRTTKDIVKERFK 29 
Homo            --MEPPLPVGAQPLATVEGMEM------KGPLREPCALTLAQRNGQYELI--IQLHEKEQ 50 
                                                                             
Drosophila      EDETIEYIFEAYQIKGPEYSNRLLALVSSQSGGTFAIIA-FSYLRTPLSSAN-------- 80 
Homo            HVQDIIPINSHFRCVQ-EAEETLLIDIASNSGCKIRVQGDWIRERRFEIPDEEHCLKFLS 109 
                                                      .     *                
Drosophila      ----------EL----------------------IINKVFAIDHNFQLRQ-DSKSSITTQ 107 
Homo            AVLAAQKAQSQLLVPEQKDSSSWYQKLDTKDKPSVFSGLLGFEDNFSSMNLDKKINSQNQ 169 
                                                      :  .: .        :       
Drosophila      QFDLSTAEDGPIKYYYYATES----HHYEEFVAKVISFKSTM--AQHDPET-----VLNF 156 
Homo            PTGIHREPPPP-----------------PFSVNKMLPREKEASNK-EQPKVTNTMRKLFV 211 
                  .                              :    :                      
Drosophila      RWLNDYRQIGEVKQELKKRESEYIVYKDIIIYCATWNVNNKTCSDSNNPLRAWLACSEKP 216 
Homo            PNTQSGQREGLIKHILAKREKEYVNIQTFRFFVGTWNVNGQSP---DSGLEPWLNCDPNP 268 
                   :   :   ::  * ::*.:*   : : .: .*:***.:      . *. **  .    
Drosophila      PDIYAIGLQELDTPTKAMLNSTQVQAIEKQWIDKMMDSVHPDVEYEILMSHRLVATMLTV 276 
Homo            PDIYCIGFQELDLSTEAFFYFES--VKEQEWSMAVERGLHSKAKYKKVQLVRLVGMMLLI 326 
                 *:*.:.:****   :*:         :  *   :  .:* . :*  :   ***. ** : 
Drosophila      IVRKQLRQHIIRCRPKSVARGIFNTLGNKGGVAISLQLNEGNICFVNSHLAAHMGYVEER 336 
Homo            FARKDQCRYIRDIATETVGTGIMGKMGNKGGVAVRFVFHNTTFCIVNSHLAAHVEDFERR 386 
                  :::   :*     ::*. *::. :*******: : ::: .:*.********    * * 
Drosophila      NQDYNAIVEGIRFDDG------RTISDHDHIFWVGDLNYRIQEPPGQQRPGPLSDAQTYE 390 
Homo            NQDYKDICARMSFVVPNQTLPQLNIMKHEVVIWLGDLNYRLCMPDANEV-KSLINKKDLQ 445 
                *:**  *   : *          .* .*: ::*:******:      :      . :  : 
Drosophila      LLLQYDQLRQEMRRGKCFEGYTEGEIKFRPTYKYDPGTDNYDSSEKQRAPAYCDRVLWKG 450 
Homo            RLLKFDQLNIQRTQKKAFVDFNEGEIKFIPTYKYDSKTDRWDSSGKCRVPAWCDRILWRG 505 
                 *  .***. :    . * .:.**.*.* ******  :* :*:* * *.**:***:**:* 
Drosophila      TRIEQLAYNSIMEIRQSDHKPVYAVFQVKVKTRDEVKYKRVQEEVLKAVDKRENDNQPQI 510 
Homo            TNVNQLNYRSHMELKTSDHKPVSALFHIGVKVVDERRYRKVFEDSVRIMDRMENDFLPSL 565 
                 .: ** *.* * :: ****** ::* : ::. :*  *::  *: :: :*: **   *.: 
Drosophila      NVEKTVIDFGTVRFNEPSTRDFNVYNNCPLPVDFSFKEK--DIHAICEPWLHVDPRQDSL 568 
Homo            ELSRREFVFENVKFRQLQKEKFQISNNGQVPCHFSFIPK-LNDSQYCKPWLRAEPFEGYL 624 
                 :.:  : *  *:: : .  .* :  *  :* .* *  *       *: ** . *    * 
Drosophila      LIDSARSIRLKMNANVRTIAGLLRKIRASD---NFDILILHVENGRDIFITVTGDYQPSC 625 
Homo            EPNETVDISLDVYVSKDSVTILNSG-----EDKIEDILVLHLDRGKDYFLTISGNYLPSC 679 
                  :.   : :.: ..  : : *             ***:**:..* * *::::*:* *** 
Drosophila      FGLSMETMCRTDRPLSEYSQDQIKQLMND-----------------ESPEYRVTMPREFF 668 
Homo            FGTSLEALCRMKRPIREVPVTKLIDLEEDSFLEKEKSLLQMVPLDEGASERPLQVPKEIW 739 
                **  :.::*   .*:       : :*                       *  : :*:*:: 
Drosophila      LLIDYLYRQGSKQVGAFPSYDSRLSLGAQFNSVRDWLDTWSDDPFPANAETAAQALLLLL 728 
Homo            LLVDHLFKYACHQEDLFQTPG----MQEELQQIIDCLDTSIPETIPGSNHSVAEALLIFL 795 
                :::*:*.: . :  . *           ::: : * ***   : : .. .:.*:***::* 
Drosophila      D-LPEHALLEPVVENLLECTNK-SQAMDYISLLSPPKRNVFMHLCMFLRAGIESQFY--- 783 
Homo            EALPEPVICYELYQRCLDSAYDPRICRQVISQLPRCHRNVFRYLMAFLRELLKFSEYNSV 855 
                : ***  :     .  *:       . : *  *   ::*** :*  **:  :: .      
Drosophila      DLHQVASTFGRILLRSTERAAWMD--Y-HSRCIQFMRLFIDTDVEAMGN-------GNEG 833 
Homo            NANMIATLFTSLLLRPPPNLMARQTPSDRQRAIQFLLGFLLGSEED-------------- 901 
                : : :*: *  :***   .         . :. :*:  *:                     
Drosophila      AGTGTGSG----SGTRAGLQA------- 850 
Homo            ---------------------------- 901 
 
Figure 3: Alignment of protein encoded by Drosophila melanogaster Ocrl with human Ocrl 
protein. 
 Clustal Omega multiple sequence alignment of Homo sapiens Ocrl protein (NP_001337156.1), 
with the Drosophila melanogaster Ocrl protein (NP_001259153.1). The domains were identified 
using the CD-search tool of NCBI Conserved Domain Database Search and Pfam. Highlighted 
are the PH-like domain (blue), INPP5c domain (green), and the RhoGAP domain (yellow).  “*” 
indicates amino acids that are identical in all sequences in the alignment. “:” indicates conserved 
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substitutions. “.” indicates semi-conserved substitutions. BLAST used to obtain protein 





Drosophila         1 I-V-KERFKPLATVEGMEMKGPLREPCALTLAQRNGQYELIIQLHEKEQ-     47 
                     : | .:   ||||||||||||||||||||||||||||||||||||||||  
Human              5 LPVGAQ---PLATVEGMEMKGPLREPCALTLAQRNGQYELIIQLHEKEQH     51 
 
Drosophila    48 -EDETIEYI---FEAYQIKGPEYSNRLLAL-VSSQSGGTFAI-I-AFSYL    90 
                       :| .|. |   |...| :. | .. || : ::|.|| . .| : . .:: 
Human              52 VQD-IIP-INSHFRCVQ-EA-E-ET-LL-IDIASNSG-C-KIRVQG-DWI    91 
 
Drosophila    91 RTPLSSANELIINKVFAI-DHNFQ-LR--QDSKSSI-TTQ    125 
                      |       |   .: |.| |.. . |:    | : : ..| 






Drosophila  4 YCATWNVNNKTCS-DSN-NPLRAWL-ACSE-KPPDIYAIGLQELD-TPTK     48 
                     :..|||||.:  | ||. .|   ||  | : .|||||.||.|||| : |: 
Human            4 FVGTWNVNGQ--SPDSGLEP---WLN-C-DPNPPDIYCIGFQELDLS-TE     45 
 
Drosophila       49 AML-N-STQVQAIEKQ-WIDKM-MD-SVHPD-VEYE-I-LMSHRLVATML     90 
                    |.. . |  |:  | | | . | :: .:| . .:|: : |:  |||..|| 
Human            46 AFFYFES--VK--E-QEW-S-MAVERGLH-SKAKYKKVQLV--RLVGMML     85 
 
Drosophila       91 TVI-VRK-QLRQHIIR-CR-PKSVARGIFNTLGNKGGVAIS-L-QLNEGN    134 
                     :| .|| |.| :| | ..  ::|..||...:|||||||:. : . |. . 
Human            86 -LIFARKDQCR-YI-RDIAT-ETVGTGIMGKMGNKGGVAVRFVFH-NT-T    129 
 
Drosophila  135 ICFVNSHLAAHMGYVEE--R-NQDY-NAIVEGIR--F-D-DGRTI-S-D-    173 
                     .|.||||||||   ||:  | |||| : |. . |  | . : :|: . :  
Human   130 FCIVNSHLAAH---VEDFERRNQDYKD-IC-A-RMSFVVPN-QTLPQLNI    172 
 
Drosophila  174 --HD-HIFWVGDLNYRI-QEPPGQQ-RPGPL-S--DAQTYELLLQYDQLR    215 
                       |:  :.|:||||||: . |...: : . | :  |.|  .|| ::|||. 
Human   173 MKHEV-VIWLGDLNYRLCM-PDANEVK-S-LINKKDLQ--RLL-KFDQLN    215 
 
Drosophila  216 -QEMRRGKCF-EGYTEGEIKF-RPTYKYDPG-TDNYDSS-EK-QRAPAYC    259 
                      |..:: |.| : :.||||||  |||||| . ||.:|||  |  |.||:| 
Human   216 IQRTQK-KAFVD-FNEGEIKFI-PTYKYD-SKTDRWDSSG-KC-RVPAWC    259 
 
Drosophila       260 DRVLWKGTRIEQL-AYNS-IMEIRQSDHKPV-YAVFQV    294 
                     ||:||:||.:.||  |.|  ||::.||||||  |:|.: 









Drosophila         1 FITVTGDY-QPSCFGLSMETMCRTDRPLSEY-S-Q--D-Q------IKQ-     37 
                     |:|::|:|  |||||.|:|.:||..||:.|. . :  | :       |:  
Human            1 FLTISGNYL-PSCFGTSLEALCRMKRPIREVPVTKLIDLEEDSFLE-KEK     48 
 
Drosophila        38 -LMN----DE-SPEYR-VTMPREFFLLIDYL--Y-R-QGSKQVGAF--PS     74 
                      |:.    || :.| | :.:|:|.:||:|:|  | . |  :.:  |  |. 
Human             49 SLLQMVPLDEGASE-RPLQVPKEIWLLVDHLFKYACHQ--EDL--FQTPG     93 
 
Drosophila        75 Y-DSRL-SLGAQFNSVRD-WLDTWS-DDP-F-P-ANAETAAQALLLLLDL    117 
                     . :. |     |.  : |  ||| |   | . | :| .:.|:|||:.  | 
Human             94 MQEE-LQ----QI--I-DC-LDT-SI--PETIPGSN-HSVAEALLIF--L    128 
 
Drosophila       118 PEHAL-LEPVV--ENLLE-CTNKSQAMDY---IS--LL-SP-PK--RNVF    154 
                      | ||  |||:  | |.: |.: | |  |   |.   : |. |:  |||| 
Human            129 -E-ALP-EPVICYE-LYQRCLD-S-A--YDPRICRQ-VISQLPRCHRNVF    169 
 
Drosophila       155 MHLCM-FLRAGI-ESQF--YD-LH-Q-VAST-F-GRILLRST-E-RA--A    191 
                     .:| | |||. :   :|  |: :: . :| | | . :|||.. . .|  . 
Human            170 RYL-MAFLRE-LL--KFSEYNSVNANMIA-TLFTS-LLLRPPPNLMARQT    213 
 
Drosophila       192 --WMDYHSRCIQFMRL    205 
                         | ..|.|||: | 
Human            214 PS--D-RQRAIQFL-L    225 
 
 
Figure 4: Pairwise Sequence Alignment of Ocrl domains.  
Alignment of human Ocrl domains with Drosophila melanogaster Ocrl domains showed PH-like 
domain (identity-43.6%; similarity-53.6%), INPP5c domain (identity-41.1%; similarity-55.3%), 






Bombus          --------------MSSSEQSMIVQSKFVSGETVIIAMDASLIQGWVKAARIIALLN--K 44 
Danio           ------------------------------------------------------------ 0 
Xenopus         ------------------------------------------------------------ 0 
Drosophila      MDTLSEAVANGTATAATRTTKDIVKERFKEDETIEYIFEAYQIKGPEYSNRLLALVSSQS 60 
Aedes           -------MSSGSH---DSAIIAAVTRKFRTGESVLAIFEVYQILGSKHQNQLLVIVSSNC 50 
                                                                             
 
Bombus          GTTHALVILITSRTPPQVYSDLTIERVLPIDQDFKCNINTDEKQQDG---LDVYLNVTSR 101 
Danio           ------------------------------------MSN--E--------------TR-- 6 
Xenopus         ------------------------------------MNYEEERQLSG---LDINLVSD-- 19 
Drosophila      GGTFAIIAFSYLRTPLSSANELIINKVFAIDHNFQLRQDSKS--SITTQQFDLSTAEDG- 117 
Aedes           --TSALFAFSISRYPPETISDLTVVAVYAIDDSFWINPESGGHGSISSHQCTV-FSHDE- 106 
                                                                             
 
Bombus          KLHLVFEMRPGV--ATSSLVSEIFRAIEVY------QKTKNSASEFLWVQKLTGNTRNLS 153 
Danio           --------------------------LDE----------RAHTANSSALKKEDESARGDA 30 
Xenopus         --------------------------LEA----------DKMAMNGQWIKANERVDPSRS 43 
Drosophila      PIKYYYYATESH--HYEEFVAKVISFKSTM----A-QHDPETVLNFRWLN---------- 160 
Aedes           PTVYYYQGTPDAIVSRDNFISKLKSLISTYKSASSQAATVSISLDFTWLD---------- 156 
                                           .                :   :.           
 
Bombus          SNTNEEIQ-DNTDPLVDLESPVLVVTRRSIASGKSPVAARESAVRYQMACKEDDYTYSKT 212 
Danio           LQSQEKVKGEVKDDLIRNSQP--VLSNKAQMLGMPQFGLRDNLIKCELLKNEDAYTYIEN 88 
Xenopus         PQMSVRHNKTTFTDLVRSADV--LSANKAEMVPFTKFGLRDNLIKSELLKNEDTYISIQN 101 
Drosophila      ----------------DYRQIG--------------------EVKQELKKRESEYIVYKD 184 
Aedes           ----------------YYKRADMLAIDRSIAEGSQAPKSRDSKFKEELERRRHEYIVYEP 200 
                                                           .: ::  ..  *   :  
 
Bombus          FRIFIGTWNVNGQPPN--GIKLREWLSYDKTPPDVYAIGFQELDLTKEAFLF--NDTPRE 268 
Danio           YSFFLGTYNVNGQTPK--E-SLSPWLASTASPPDFYLIGFQELDLSKEAFLF--NDTPKE 143 
Xenopus         YRFFVGTYNVNGQSPR--E-SLQTWLSQDSEPPDLYCIGFQELDLSKEAFFF--NDTPKE 156 
Drosophila      IIIYCATWNVNNKTCSDSNNPLRAWLACSEKPPDIYAIGLQELDTPTKAMLNSTQVQAIE 244 
Aedes           YKIYTATWNVNGQTSE--NIELPEWLSTTEDPPDIYAVGFQEIEWTPEKIIM--NETKID 256 
                  :: .*:***.:        *  **:    ***.* :*:**::   : ::   :    : 
 
Bombus          EEWRQVVAKSLHPDGVYEQVAIVRLVGMMLLIYALHGHIPYIKDVSVDTVGTGIMGKMGN 328 
Danio           PEWMLAVYKGLHPDAKYALVKLVRLVGIMLLFYVKAEHAPHISEVEAETVGTGVMGRMGN 203 
Xenopus         EEWFKAVSDGLHPEAKYAKIKLIRLVGIMLLLYVKKELAVHVSEVEAETVGTGIMGRMGN 216 
Drosophila      KQWIDKMMDSVHPDVEYEILMSHRLVATMLTVIVRKQLRQHIIRCRPKSVARGIFNTLGN 304 
Aedes           RTWVDKVMSGLHNGAEYEEVASVRLVGMMLTVAVKKSLRDRISDCLTAAVGTGTL-KWGN 315 
                  *   : ..:*    *  :   ***. ** . .       :      :*. * :   ** 
 
Bombus          KGGVAVSCSIHNTSICFVNAHLAAHCEEYERRNQDYADICARLSFAKY---VPPKSFKDH 385 
Danio           KGAVSIRFQFHNSDICVVNSHLAAHTEEFERRNQDFKDICRRIQFRQEDPTLPPLTILKH 263 
Xenopus         KGGVAIRFRFHNTHLCIVNSHLAAHVDEFERRNQDFREICSRMQFAQADPTLSPLTIHKH 276 
Drosophila      KGGVAISLQLNEGNICFVNSHLAAHMGYVEERNQDYNAIVEGIRFD------DGRTISDH 358 
Aedes           KGGVGVSFQMNEALFCFVNTHLAAHTQEVERRNEDHDEIIRRMSFEKT---FRGRSIDEH 372 
                **.*.:   :::  :*.**:*****    *.**:*.  *   : *          :: .* 
 
Bombus          DQIYWLGDLNYRITEMD-VLVAKQHIDAENYAPILALDQLGQQRRLGRVLQGFQEAEITF 444 
Danio           NIVLWLGDLNYRISDLE-VDHVKDLISKKDFETLHTYDQLKRQMDEEVVFVGFTEGEIDF 322 
Xenopus         DVVLWLGDLNYRLKDIE-LEKVKKLIDSRDYKTLHKFDQLKQQIDGKAVFEGFTEGEIMF 335 
Drosophila      DHIFWVGDLNYRIQEPPGQQRPGPLSDAQTYELLLQYDQLRQEMRRGKCFEGYTEGEIKF 418 
Aedes           HHIFWIGDLNYRLSGDVSQEAVN--LKDGDYNQLYPFDQLYVEKLRKRIFRGYNEGKILF 430 
                . : *:******:             .   :  :   ***  :      : *: *.:* * 
 
Bombus          KPTYKYDPGTDNWDSSEKGRAPAWCDRILWKGEAITSIDYKSHPELKISDHKPVSAIFDS 504 
Danio           QPTYKYDTGSDQWDTSEKCRVPAWCDRILWRGKSIKQLHYQSHMTLKTSDHKPVSSLLEI 382 
Xenopus         QPTYKYDPGTDEWDTSEKCRTPAWCDRVLWKGKHITQLEYRSHMALKTSDHKPVSSLFDI 395 
Drosophila      RPTYKYDPGTDNYDSSEKQRAPAYCDRVLWKGTRIEQLAYNSIMEIRQSDHKPVYAVFQV 478 
Aedes           CPTYKYNPGTDDWDSSEKSRCPAWCDRVLWKGQRMELLKYDSVMQLRRSDHKPVYAVFNV 490 




Bombus          QIRIIDMTKYRKIHEEVMKKLDKLENEFLPQVMVDTTEIIFDTLKFLEPSSKELIIANTG 564 
Danio           GIKVVNEESYKRTFEEIVRQIDRLENDCIPSVSLSEREFHFQDVKFMQHQARTVTVHNDG 442 
Xenopus         GVKVVNEELYKKTFEEIVRCLDKMENDCIPSAALSQREFHFKDVKYRQLQVQTFTIHNDG 455 
Drosophila      KVKTRDEVKYKRVQEEVLKAVDKRENDNQPQINVEKTVIDFGTVRFNEPSTRDFNVYNNC 538 
Aedes           DVETKDDHKFKRVHEEVLKTVDKYENDNQPQITVEQTDLDFGLIRFNERYSRELLVANNC 550 
                 :.  :   :::  **::: :*: **:  *.  :.   : *  ::: :   : . : *   
 
Bombus          QVPVQFEFIKKLG-DASYCKDWLDIEPFKGFIKPGEKCDTRFEIYVDKRSACKLN----- 618 
Danio           QVPCQFEFIQKLD-EPAYCKPWLTANPAKGFLAQGASVDIDLEVFVNRHTAPELN----- 496 
Xenopus         QVACQFEFIRKLD-EESYSKPWLRANPSKGFLTPGSSMQIELEVFVNNQTAAALN----- 509 
Drosophila      PLPVDFSFKEKD--IHAICEPWLHVDPRQDSLLIDSARSIRLKMNANVRTIAGLLRKIRA 596 
Aedes           HLPVQFNFSAKDDRNSSVCEEFIHISKKSGELLTGDSRSIRIDIFIDAKAASKMLKKLKD 610 
                 :  :*.*  *     : .: ::  .  .. :  .   .  :.:  : ::   :       
 
Bombus          --SGEDKLYDILILHLEGGKDIFITVTGTYERSCFGSSMEALVHIPVPIREIPIGRLMEL 676 
Danio           --AGLQQLEDILVLHLERGKDYFISITGSYLPSCFGSSLSALCLLREPIQDMPLESIREL 554 
Xenopus         --AAEEKIEDILILHLDRGKDFFLSVTGNYLHSCFGSSIQMLCYMNGYMRDTSEETITQL 567 
Drosophila      -----SDNFDILILHVENGRDIFITVTGDYQPSCFGLSMETMCRTDRPLSEYSQDQIKQL 651 
Aedes           AKAGVKIPLDILVLHVKNGRDIFITIFGEYKSSCFGLSLDTLIKLTKPVFEYEINELIAM 670 
                     .   ***:**:. *:* *::: * *  **** *:. :      : :     :  : 
 
Bombus          EN-------NKNLSQEPYAIPKEIWLLVDRLYRHGIKTTGLFETP----GLPSEIIAIRD 725 
Danio           SVKS--NSPVIDSADKPQEIPKEIWMMVDHLFRYAKKQEDLFQQP----GLRSEFEEIRD 608 
Xenopus         AQMPLQMKDNFLGAEKPAKIPKELWMMVDHLYRNASQQEDLFQQP----GLMSEFEAIRD 623 
Drosophila      MN--------DESPEYRVTMPREFFLLIDYLYRQGSKQVGAFPSYDSRLSLGAQFNSVRD 703 
Aedes           EREEK---LVDLNNSTDLKVPREIWRLIDYLYTEGMDTHQLFVNR--AYGQHENIVEIRD 725 
                              .    :*:*:: ::* *:  . .    *       .   ::  :** 
 
Bombus          WLDNWSQDPMPGSVHSVAEALLLLLESTAEPLIPYNLHSVCLSAATNYLQCKQIV-MQLP 784 
Danio           CLDTGCLDTLPGSNHSVAEALLLFLDALPEPVIPFSFYQQCLDCCSDSSHCRQII-SMLP 667 
Xenopus         CLDSGYPESLPGSNHSVVEALLLFLEALPEPVICYQSYQKCLESIGDYSSSKEVV-SMLP 682 
Drosophila      WLDTWSDDPFPANAETAAQALLLLLDLPEHALLE-PV-VENLLECTNKSQAMDYI-SLLS 760 
Aedes           WLDSWSSAPCPATPKTAAEALLIFLESLPEPLVTISE-RECIVNADNYERCRELIRVKLK 784 
                 **.      *.. .:..:***::*:   . ::        :    :   . : :   *  
 
Bombus          EIRRTVFVYICYFLQELLNHTQDNELDAKTLATIFGSIFLRDPPRSRCDRNQSSRTQIIQ 844 
Danio           QCHKNVFNYLTAFLQELLRHSAYNRLDVNVVAPIFAGLLLRSPDKQ---DINE------- 717 
Xenopus         LHHKNVFKYLISFLQEMLNNSEKNHLDIKILASIFGNLLLRPPPDLPKPSNSD------- 735 
Drosophila      PPKRNVFMHLCMFLRAGI-ESQF--YDLHQVASTFGRILLRSTERAAWMDYHS------- 810 
Aedes           PVNRIIFLHICLFLIELQRKNPS--VRLNNLATTFGRILIRSQLTPGRTPTGNDVY-AYT 841 
                  .: :* ::  **     ..       : :*  *. :::*           .        
 
Bombus          ATIDRKKAAFVYHFLVNDQSDFILGR------------------- 870 
Danio           ---KRKVKEFFQHFLVQTSSDRDIHEKSPE--------------- 744 
Xenopus         ---KRRCQEFVQQFLQPEDP------------------------- 752 
Drosophila      -----RCIQFMRLFIDTDVEAMGNGNEGAGTGTGSGSGTRAGLQA 850 
Aedes           EGERDQRRRFMMTFLTNN-----NGVQEFARAEMNGTGM------ 875 
                     :   *.  *:                               
Figure 5: Alignment of human Ocrl protein with similar protein from selected vertebrates 
and invertebrates. 
Clustal Omega multiple sequence alignment of Homo sapiens Ocrl protein (NP_001337156.1), 
with the Zebrafish uhrf1bp1l Danio rerio (XP_017206941.1) and frog uhrf1bp1l  Xenopus laevis 
(accession number XP_002939536.2), buff-tailed bumblebee (Bombus terrestris 
(XP_012169971.1), honey bee (Aedes aegypti (XP_021709736.1) and D. melanogaster 
(NP_001259153.1). The domains were identified using the CD-search tool of NCBI Conserved 
Domain Database Search and Pfam. Highlighted are the PH-like domain (blue), INPP5c domain 
(green), and the RhoGAP domain (yellow).  “*” indicates amino acids that are identical in all 
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sequences in the alignment. “:” indicates conserved substitutions. “.” indicates semi-conserved 
substitutions. BLAST used to obtain protein sequences and Pfam (Sanger Institute) used to obtain 
conserved domain areas. 
 
Eye analysis 
    The D. melanogaster eye is a precise model with which to decrypt mechanisms of neural 
differentiation. Each eye consists of approximately 750 to 800 ommatidia containing eight 
photosensitive neurons. The presence of such a large number of neurons (>6000), makes the D. 
melanogaster eye an extremely useful tool to study many aspects of neural development. Any 
neurodegeneration may lead to changes in ommatidia and interommatidial bristle numbers. To 
examine the phenotypic changes in the eye, biometric analysis was conducted to determine the 
effects of overexpression and RNA-interference of Ocrl on the development of neurons. These 
phenotypic changes include a change in the number of ommatidia or interommatidial bristles in 
comparison to the control. The eye specific transgenic line GMR-Gal4 was used to express Ocrl 
transgenes.  
Inhibition of Ocrl decreases ommatidia and interommatidial bristle number 
Biometric analysis of the scanning electron micrographs reveals that there is a significant 
decrease in ommatidia and interommatidial bristle number when the inhibition of Ocrl is driven 
by GMR-GAL4 (Figures 6 and 7). The average number of ommatidia for GMR-GAL4; UAS-Ocrl-
RNAiKK, C: GMR-GAL4; UAS-Ocrl-RNAiGD, D: GMR-GAL4; UAS-Ocrl-RNAiHMS was 628.3 ± 
13.85, 579.5 ± 6.21 and 606.7 ± 5.4, respectively in comparison to the control lacZ where the 
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average number of ommatidia per eye was 658.5 ± 10.48 (P < 0.0001). The average 
interommatidial bristle number for GMR-GAL4; UAS-Ocrl-RNAiKK, C: GMR-GAL4; UAS-Ocrl-
RNAiGD, D: GMR-GAL4; UAS-Ocrl-RNAiHMS was 592.2 ± 10.08, 502.3 ± 9.8 and 531.9 ± 10.04, 
respectively. The average number of interommatidial bristles in the control lacZ was 613.3 ± 11.59 
(Table 3).  
Overexpression of Ocrl decreases ommatidia and interommatidial bristle number 
The Ocrl and the control line UAS-lacZ were expressed in the eye to determine whether 
they cause a rough eye phenotype during eye development. Analysis of scanning electron 
micrographs of eyes shows that there is a significant decrease in ommatidia number and 
interommatidial bristle number when Ocrl is overexpressed in the eye using the GMR-GAL4 driver 
(Figures 6 and 8). The average ommatidia number for the overexpression of Ocrl is 579.4 ± 13.85 
and for the control lacZ is 658.5 ± 10.48. The average interommatidial bristle number for the 
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Figure 6: Compound eye of Drosophila melanogaster with altered Ocrl expression 
visualized by scanning electron microscopy. 
 A) GMR-GAL4; UAS-lacZ, B) GMR-GAL4; UAS-Ocrl-RNAiKK, C) GMR-GAL4; UAS-Ocrl-
RNAiGD, D) GMR-GAL4; UAS-Ocrl-RNAiHMS   E) GMR-GAL4; UAS-OcrlEY. There is a 
significant difference in the number of ommatidia or interommatidial bristles in comparison to 
























































































































































































        A                                                                             B 
Figure 7: Biometric analysis of the Drosophila melanogaster eye under the influence of eye 
specific expression with the inhibition of Ocrl. Inhibition of Ocrl in the eye significantly 
decreases ommatidia number (A) and interommatidial bristle number (B). UAS-lacZ crosses are 
the comparison controls. Comparisons were measured using a one-way ANOVA. Asterisks indicate 















Table 3: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
inhibited in the compound eye. 
Genotype                         Sample Size       Mean ± SEM                 p-value              Significant              
              (n)                                                          compared  
                                                                              to control                                                     
Ommatidia 
number 
GMR-GAL4;                        10                   658.5 ± 10.48                   N/A                      N/A 
UAS-lacZ 
GMR-GAL4;                       10                   606.7 ± 5.4                      <0.0001                  Yes 
UAS-Ocrl-RNAiHMS 
GMR-GAL4;                       10                   628.3 ± 13.85                   0.0373                   Yes 
UAS-Ocrl-RNAiKK 
GMR-GAL4;                       10                   579.5 ± 6.21                    <0.0001                  Yes 
UAS-Ocrl-RNAiGD 
Interommatidial Bristle number 
GMR-GAL4;                        10                  613.3 ± 11.59                     N/A                    N/A 
UAS-lacZ 
GMR-GAL4;                       10                  531.9 ± 10.04                   <0.0001                 Yes 
UAS-Ocrl-RNAiHMS 
GMR-GAL4;                       10                  592.2 ± 10.08                    <0.0001                Yes 
UAS-Ocrl-RNAiKK 

















































































































A                                                                                             B 
Figure 8. Overexpression of Ocrl gene in the compound eye with eye-specific driver GMR-
Gal4. Overexpression of Ocrl in the eye significantly decreases ommatidia number (A) and 
interommatidial bristle number (B). UAS-lacZ crosses are the comparison controls. Comparisons 
were measured using a one-way ANOVA and significance was tested by unpaired t-test (P<0.05), 














Table 4: Summary of ommatidia number and interommatidial bristle number when Ocrl is 
overexpressed. 
Genotype                         Sample Size       Mean ± SEM                 p-value              Significant              
              (n)                                                          compared  
                                                                              to control                                                     
Ommatidia 
number 
GMR-GAL4;                        10                   658.5 ± 10.48                   N/A                        N/A 
UAS-lacZ 
GMR-GAL4;                       10                   579.4 ± 13.85                   0.0373                    Yes 
UAS-OcrlEY 
Interommatidial Bristle number 
GMR-GAL4;                        10                  546.4 ± 11.59                     N/A                       N/A 
UAS-lacZ 


















Effects of the Overexpression of Ocrl upon Longevity and Climbing Ability 
There are different systems to address neurodegeneration and neuronal dysfunction in D. 
melanogaster. Some of these systems address parameters of fly behavior like locomotion and 
longevity. Degeneration of dopaminergic neurons is an important characteristic of PD. The 
systematic death of these dopaminergic neurons and their degeneration lead us to 
investigate the effects of Ocrl on these neurons. A standard control and experimental lines were 
overexpressed and silenced by RNAi and directed by the D42-Gal4, TH-Gal4 and ddc-Gal4 
transgenes to determine the phenotypic (ageing and climbing) effects of Ocrl transgenes on the 
dopaminergic and motor neuronal. 
To investigate the effects of the overexpression of Ocrl on climbing ability and lifespan of 
D. melanogaster, the motor neuron specific driver D42-GAL4, the neuron specific transgene ddc-
GAL4 and TH-GAL4 were used. When the motor neuron specific transgene D42-GAL4 was used, 
there was a significant difference found in the climbing ability of flies with the overexpression of 
Ocrl when compared to the control UAS-lacZ (Figures 9, Table 5). However, when using the 
neuron specific transgene ddc-GAL4 and TH-GAL4 there was no significant difference in the 
climbing ability of flies between ddc-GAL4; UAS-OcrlEY and TH-GAL4; UAS-OcrlEY when 
compared to the control ddc- GAL4; UAS-lacZ and TH- GAL4; UAS-lacZ (Figure 10, Table 6) and 
(Figure11, Table 7), respectively.  
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The overexpression of Ocrl using the motoneuron specific transgene, D42-GAL4 and ddc-
GAL4 neuron specific transgene resulted in a decrease in lifespan of flies in comparison to the 
control UAS-lacZ (Figures 12, Table 8) and (Figure 13, Table 9), respectively. However, the 
overexpression of Ocrl using the TH-GAL4 showed a significant increase in lifespan of flies in 
comparison to the control UAS-lacZ (Figures 14, Table 10). The median lifespan for flies with an 
overexpression of OCRL with transgene TH-GAL4 is 52 days which is longer than the control TH- 


































Figure 9: Overexpression of Ocrl in the motor neurons causes a significant decrease 
in climbing ability of flies. Data was analyzed by a non-linear curve fit with 95% 
confidence intervals. Significance was tested by unpaired t-test (P<0.05). Error bars 
represent standard error and n=50. 
 
Table 5: Comparison of climbing ability flies with overexpression of Ocrl in the 
motor neurons using Log-rank test. p-values were calculated using lacZ-expressing 






     p-value Significant 
D42-GAL4; UAS-lacZ 0.1191 0.2096 to 0.8647       N/A       N/A 
D42-GAL4; UAS-
OcrlEY 




























Figure 10: Overexpression of Ocrl in the dopaminergic and serotonergic neurons 
does not cause a significant decrease in climbing ability of flies. Data was analyzed by 
a non-linear curve fit with 95% confidence intervals. Significance was tested by unpaired 
t-test (P<0.05). Error bars represent standard error and n=50. 
 
Table 6: Comparison of climbing ability of flies with overexpression of Ocrl in the 
dopaminergic and serotonergic neurons using Log-rank test. p-values were calculated 







ddc-GAL4; UAS-lacZ 0.1018 0.6712 to 2.030 N/A N/A 




























Figure 11: Overexpression of Ocrl in the dopaminergic neurons does not cause a 
significant decrease in climbing ability of flies. Data was analyzed by a non-linear 
curve fit with 95% confidence intervals. Significance was tested by unpaired t-test 
(P<0.05). Error bars represent standard error and n=50. 
 
Table 7: Comparison of climbing ability of flies with overexpression of Ocrl in the 
dopaminergic neurons using Log-rank test. p-values were calculated using lacZ-






TH-GAL4; UAS-lacZ 0.1125 0.6965 t0o 1.295 N/A N/A 




























Figure 12: Overexpression of Ocrl in the motor neurons causes a decrease in 
longevity of flies. Longevity is depicted by percent survival. Significance is p <0.05 
using the log-rank test. Significance was determined at 95%, at a P value less than or 
equal to 0.05 with Bonferroni correction. Error bar represents standard error and n=300. 
 
Table 8: Comparison of survival of flies with overexpression of Ocrl in the motor 






with Bonferroni  
correction 
Significant 




































Figure 13: Overexpression of Ocrl in the dopaminergic and serotonergic neurons 
causes a decrease in longevity of flies. Longevity is depicted by percent survival. 
Significance is p <0.05 using the log-rank test. Significance was determined at 95%, at a 
P value less than or equal to 0.05 with Bonferroni correction. Error bar represents 
standard error and n= 300. 
 
Table 9:  Comparison of survival of flies with overexpression of Ocrl in the 
dopaminergic and serotonergic neurons using Log-rank test.  p-values were 









ddc-GAL4;  UAS-lacZ 300 57 N/A      N/A 
ddc-GAL4; UAS-OcrlEY 300 42 <0.0001 
 






























Figure 14: Overexpression of Ocrl in the dopaminergic neurons causes a significant 
increase in longevity of flies. Longevity is depicted by percent survival. Significance is 
p <0.05 using the log-rank test. Significance was determined at 95%, at a P value less 
than or equal to 0.05 with Bonferroni correction. Error bar represents standard error and 
n=300. 
 
Table 10: Comparison of survival of flies with overexpression of Ocrl in the 
dopaminergic neurons using Log-rank test. p-values were calculated using lacZ-






with Bonferroni  
correction 
Significant 
TH-GAL4;  UAS-lacZ 300 44 N/A     N/A 
TH-GAL4; UAS-
OcrlEY 








Effects of the Inhibition of Ocrl upon Longevity and Climbing Ability 
To examine the effects of the inhibition of Ocrl on climbing ability and lifespan of D. 
melanogaster, the motor neuron specific driver D42-GAL4, the dopaminergic neuron specific 
driver TH-GAL4 and the dopaminergic and serotonergic neuron specific driver ddc-GAL4 were 
used. The inhibition of Ocrl using the motor neuron specific driver D42-GAL4 resulted in a 
significant decrease in the climbing ability of flies. (Figure 15, Table 11). When using the TH-
GAL4, there was a significant decrease in the climbing ability of flies between TH-GAL4; UAS-
Ocrl-RNAiKK, and the control TH-GAL4; UAS-lacZ. Same results were obtained between TH-
GAL4; UAS-Ocrl-RNAiHMS and TH-GAL4; UAS-lacZ (Figure 16, Table 12). The inhibition of Ocrl 
using the ddc-GAL4; UAS-Ocrl-RNAiHMS resulted in a significant decrease in climbing ability of 
flies when compared to the control UAS-lacZ (Figure 17, Table 13).  
The inhibition of Ocrl using the motor neuron-specific driver D42-GAL4 and the UAS-
Ocrl-RNAiKK and UAS-Ocrl-RNAiGD resulted in a significant decrease in lifespan in comparison to 
the control UAS-lacZ (Figures 18, Table 14). The inhibition of Ocrl using the dopaminergic neuron 
specific driver TH-GAL4 (Figure 19, Table 15) and ddc-GAL4 (Figure 20, Table 16) resulted in no 
significant change in the lifespan of flies when compared to the control UAS-lacZ. 
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Figure 15: Inhibition of Ocrl in motor neurons causes a significant decrease in 
climbing ability of flies. Data was analyzed by a non-linear curve fit with 95% 
confidence intervals. Significance was tested by unpaired t-test (P<0.05). Error bars 
represent standard error and n=50. 
 
 
Table 11: Comparison of climbing ability of flies with inhibition of Ocrl in the motor 










0.1606 0.2096 to 0.8647 N/A N/A 
D42-GAL4; UAS-Ocrl-
RNAiKK 

















































Figure 16: Inhibition of Ocrl in dopaminergic neurons causes a significant decrease 
in climbing ability of flies. Data was analyzed by a non-linear curve fit with 95% 
confidence intervals. Significance was tested by unpaired t-test (P<0.05). Error bars 
represent standard error and n=50. 
 
 
Table 12: Comparison of climbing ability of flies with inhibition of Ocrl in the 
dopaminergic neurons using Log-rank test. p-values were calculated using lacZ-







TH-GAL4; UAS-lacZ 0.1125 
 




























































Figure 17: Inhibition of Ocrl in dopaminergic and serotonergic neurons causes a 
significant decrease in climbing ability of flies. Data was analyzed by a non-linear 
curve fit with 95% confidence intervals. Significance was tested by unpaired t-test 
(P<0.05). Error bars represent standard error and n=50. 
 
 
Table 13: Comparison of climbing ability of flies with inhibition of Ocrl in the 
dopaminergic and serotonergic neurons using Log-rank test. p-values were calculated 

























































Figure 18: Inhibition of Ocrl in the motor neurons causes a decrease in longevity of 
flies. Longevity is depicted by percent survival. Significance is p <0.05 using the log-
rank test. Significance was determined at 95%, at a P value less than or equal to 0.05 with 
Bonferroni correction. Error bar represents standard error and n=300. 
 
 
Table 14: Comparison of survival of flies with inhibition of Ocrl in the motor 



































































Figure 19: Inhibition of Ocrl in the dopaminergic neuron does not cause a 
significant decrease in longevity. Longevity is depicted by percent survival. 
Significance is p <0.05 using the log-rank test. Significance was determined at 95%, at a 
P value less than or equal to 0.05 with Bonferroni correction. Error bar represents 
standard error and n=300. 
 
 
Table 15: Comparison of survival of flies with inhibition of Ocrl in the dopaminergic 






























































Figure 20: Inhibition of Ocrl in the dopaminergic and serotonergic neurons does not 
cause a significant decrease in longevity of flies. Longevity is depicted by percent 
survival. Significance is p <0.05 using the log-rank test. Significance was determined at 
95%, at a P value less than or equal to 0.05 with Bonferroni correction. Error bar 
represents standard error and n=300. 
 
Table 16: Comparison of survival of flies with inhibition of Ocrl in the dopaminergic 







































Expression of Ocrl in the park interference model of PD 
I co-expressed Ocrl in DA neurons along with park (ddc-GAL4/CyO; UASpark-
RNAi/TM3) to investigate whether it possesses neuroprotective functions by evaluating the 
phenotypes that would result from inhibition of Ocrl and expression of park. Eye experiment, 
ageing and climbing ability were analyzed and compared to results obtained in park- RNA 
interference expressing control flies.  
Eye analysis of the control and experimental lines in park model. 
Our standard control line UAS-lacZ and the experimental lines Ocrl, were crossed to the 
derivate line GMR-GAL4; UAS-park-RNAi to analyze the number of ommatidia and 
interommatidial bristle. Biometric analysis of the scanning electron micrographs shows that the 
overexpression of Ocrl along with park expression resulted in worsened eye phenotypes, and the 
number of ommatidia interommatidial bristle was lower when compared to controls. (Figures 21, 
Table 17). In addition, there was a significant decrease in the number of ommatidia and 
interommatidial bristle with the inhibition of Ocrl and with park expression in dopaminergic 










































































































































A                                                                                                                    B 
 
Figure 21: The overexpression of Ocrl along with park expression in ddc-Gal4-
expressing neurons. Overexpression of Ocrl with inhibition of park in a transgene line 
in the eye causes a significant decrease ommatidia number (A) and interommatidial 
bristle number (B). Significance is <0.05. Error bars represent standard error of the 

















Table 17: Summary of ommatidia number and interommatidial bristle number when Ocrl 
is overexpressed and park is inhibited in the developing eye. 
  
Genotype                         Sample Size       Mean ± SEM                 p-value              Significant              
              (n)                                                          compared  
                                                                              to control                                                     
Ommatidia 
number 
GMR-GAL4;                        10                   705.3 ± 12.45                   N/A                        N/A 
UAS-park-RNAi;  
UAS-lacZ 
GMR-GAL4;                       10                   667.1 ± 10.84                   0.01                       Yes 
UAS-park-RNAi;  
UAS-OcrlEY 
Interommatidial Bristle number 
GMR-GAL4;                        10                  568.1 ± 9.58                     N/A                        N/A 
UAS-park-RNAi;  
UAS-lacZ 



















































































































































































































































        A                                                                             B 
Figure 22: The inhibition of Ocrl along with park expression in ddc-Gal4-
expressing neurons. Inhibition of Ocrl with inhibition of park in a transgene line in 
the eye causes a significant decrease in ommatidia number (A) and interommatidial 
bristle number (B). Significance is <0.05. Error bars represent standard error of the 






















Table 18: Summary of ommatidia number and interommatidial bristle number when Ocrl 
is inhibited and park is inhibited in the developing eye. 
 
Genotype                         Sample Size       Mean ± SEM                 p-value              Significant              
              (n)                                                          compared  
                                                                              to control                                                     
Ommatidia 
number 
GMR-GAL4;                        10                   700.4 ± 7.32                   N/A                        N/A 
UAS-park-RNAi 
UAS-lacZ 
GMR-GAL4;                       10                   688.6 ± 4.21                   0.0124                    Yes 
UAS-park-RNAi 
UAS-Ocrl-RNAiHMS 
GMR-GAL4;                       10                   685.5 ± 4.28                   0.0022                     Yes 
UAS-park-RNAi 
UAS-Ocrl-RNAiKK 
GMR-GAL4;                       10                   686.7 ± 4.22                   0.0057                     Yes 
UAS-park-RNAi 
UAS-Ocrl-RNAiGD 
Interommatidial Bristle number 
GMR-GAL4;                        10                  580.4 ± 6.07                     N/A                     N/A 
UAS-park-RNAi 
UAS-lacZ 
GMR-GAL4;                        10                 536.3 ± 3.31                    0.0016                    Yes 
UAS-park-RNAi 
UAS-Ocrl-RNAiHMS 
GMR-GAL4;                        10                  537.1 ± 3.62                     0.0015                  Yes 
UAS-park-RNAi 
UAS-Ocrl-RNAiKK 










Longevity analysis of the control and experimental lines in the park model 
The co-expression of Ocrl transgenes with parkin showed different survival curves. 
The inhibition of Ocrl using the recombinant line ddc-GAL4;UAS-park-RNAi decreased the 
lifespan of flies in comparison to the control UAS-lacZ (Figure 23, Table 19). Median survival for 
ddc-GAL4; UAS-park-RNAi; UAS-Ocrl-RNAiKK, ddc-GAL4; UAS-park-RNAi; UAS-Ocrl-RNAiGD 
and ddc-GAL4; UAS-park-RNAi; UAS-Ocrl-RNAiHMS was 48, 49 and 46 respectively, which varied 
compare to the 52 days of control lacZ. No significant difference was found in the lifespan of flies 
































Figure 23: The inhibition of Ocrl along with park expression in ddc-Gal4-expressing 
neurons cause a significant decrease in longevity. Longevity is depicted by percent 
survival. Significance is p <0.05 using the log-rank test. Significance was determined at 
95%, at a P value less than or equal to 0.05 with Bonferroni correction. Error bar 
represents standard error and n=300. 
  
Table 19: Comparison of longevity of flies with inhibition of Ocrl along with park 
expression in the ddc-Gal4-expressing neurons by Log-rank test. p-values were 
































































Figure 24: The overexpression of Ocrl along with park expression in the ddc-Gal4-
expressing neurons does not cause a significant decrease in longevity. Longevity is 
depicted by percent survival. Significance is p <0.05 using the log-rank test. Significance 
was determined at 95%, at a P value less than or equal to 0.05 with Bonferroni correction. 
Error bar represents standard error and n=300. 
 
Table 20: Comparison of longevity of flies with overexpression of Ocrl along with 
park expression in the ddc-Gal4-expressing neurons by Log-rank test. p-values were 





























Climbing analysis of the control and experimental lines in park model 
Loss of locomotor ability is one of the significant characteristic of PD phenotypes as well 
as park RNAi regulated model of PD. Therefore, the contribution role of Ocrl gene alteration in 
park inhibition models is worth detecting. To investigate the likely effect in the dopaminergic 
neurons three inhibition lines UAS-Ocrl-RNAiKK, UAS-Ocrl-RNAiGD and UAS-Ocrl-RNAiHMS and 
one overexpression line UAS-OcrlEY were crossed with the derivate line ddc-Gal4; UAS-park-
RNAi. Directed inhibition of Ocrl using the recombinant line ddc-GAL4; UAS-park-RNAi had no 
significant improvement is lifespan of flies. When the recombinant line ddc-GAL4; UAS-park-
RNAi was used, there was no significant difference found in the climbing ability of flies with the 
inhibition of Ocrl when compared to the control UAS-lacZ (Figure 25). The 95% confidence 
interval for the flies produced from crossing of UAS-Ocrl-RNAiKK, UAS-Ocrl-RNAiGD , UAS-Ocrl-
RNAiHMS and UAS-lacZ, with ddc-Gal4;UASpark-RNAi was 0.3706 to 1.249, 0.3374 to 1.315, 
0.5347 to 1.289 and 0.6965 to 1.295, respectively (Table 21). There was no significant difference 
in the climbing ability of flies with the overexpression of Ocrl along with park expression in the 


































Figure 25: The inhibition of Ocrl along with park expression in ddc-Gal4-expressing 
neurons had no significant difference in climbing ability of flies when compared to 
the control. Data was analyzed by a non-linear curve fit with 95% confidence intervals. 




Table 21: Comparison of climbing ability of flies with inhibition of Ocrl along with 
park expression in the ddc-Gal4-expressing neurons by Log-rank test. p-values were 
calculated using lacZ-expressing controls and n=50. 
Genotype Standard 
























































Figure 26: The overexpression of Ocrl along with park expression in ddc-Gal4-
expressing neurons had no significant difference in climbing ability of flies when 
compared to the control. Data was analyzed by a non-linear curve fit with 95% 
confidence intervals. Significance was tested by unpaired t-test (P<0.05). Error bars 
represent standard error and n=50. 
 
Table 22: Comparison of climbing ability of flies with overexpression of Ocrl along 
with park expression in the ddc-Gal4-expressing neurons by Log-rank test.  p-values 









0.1556 0.6965 to 1.295 N/A N/A 
ddc-GAL4; UAS-park-
RNAi; UAS-OcrlEY 












Parkinson Disease (PD) is the second most common neurodegenerative disorder. The 
prevalence of PD increases steadily with age. Although several genes have been implicated, the 
cellular pathways and molecular mechanisms behind the progression of PD are still mostly 
unknown (De Lau et al., 2004). The exact role of Ocrl in the pathogenesis of PD is being 
investigated after being identified as a risk factor in a genome-wide association study (Jansenet 
al., 2017). The aim of this study was to determine the different aspects of the Drosphila 
melanogaster homologue of human Ocrl. Ocrl was inhibited and overexpressed in dopaminergic, 
serotonergic and motor neurons of D. melanogaster to investigate its role in longevity, locomotor 
ability, and eye development to recapitulate the phenotypic symptoms of PD.    
Sequence alignment of human Ocrl and its homologue in flies was performed using the 
bioinformatics tool to identify similarity and identity. These two sequences showed more than 
32.7% identity and 47.7% similarity in their amino acid sequences and they share the conserved 
domain INPP5c and RhoGAP, indicating that D. melanogaster Ocrl is closely homologue to 
human Ocrl. Alignment of Drosophila Ocrl with four invertebrate and vertebrate species further 
indicates the evolutionary conservation of amino acid sequences. Same domains INPP5c and 
RhoGAP are well conserved among all the different protein sequences.  
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Ocrl has been localized to various endolysosomal compartments suggesting impairments 
in this system as a possible disease mechanism. Recent evidence strongly supports this view and 
indicates important Ocrl functions in clathrin-coated pits, cargo transport from the endosomes to 
the trans-Golgi network as well as receptor recycling from endosomes to the plasma membrane. 
Overexpression of Ocrl lacking its 5-phosphatase domain results in a transport deficiency of cargo 
proteins such as CI-MPR and Shiga toxin B-subunit to the trans-Golgi network (Choudhury et al., 
2005). Alternatively, introducing inhibition of Ocrl with RNAi results in a slowing of endosome 
to trans-Golgi network transport rates (Choudhury et al., 2005). These results together, 
demonstrate the crucial role of Ocrl for proper trans-Golgi network membrane trafficking. In 
particular, both in vitro and in vivo evidence demonstrates a significant role of Ocrl in the 
recycling of megalin, a multi-ligand receptor that is essential for nutrient reabsorption of nutrients 
in the proximal tubules, a process that is severely impaired in patients with Lowe syndrome. 
Therefore, it is plausible that impairments in the endocytic pathway contribute to the kidney 
pathology in Lowe syndrome and Dent-II disease (Sharma et al., 2015). A transgenic zebrafish 
model of Lowe syndrome was developed by injecting a retrovirus into the Ocrl promoter, 
interfering with its expression. (Ramirez et al., 2012). Zebrafish embryos deficient for Ocrl are 
more vulnerable than wild‑type embryos to febrile seizures and show cystic lesions in the brain 
(Ramirez et al., 2012). Furthermore, loss of Ocrl impairs cell survival and reduces the proliferation 
rate in various cells, but particularly in neuronal tissues during development. In addition, loss of 
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Ocrl results in the defective fluid phase and clathrin‑mediated endocytosis in the zebrafish 
pronephric tubule - the region with the highest similarity to the proximal tubule of humans. This 
defect in pronephric tubule endocytosis relies on Ocrl catalytic activity and on its ability to interact 
with the clathrin machinery since it can be rescued by re‑expressing Ocrl's fully functional, but 
not clathrin-binding, mutant forms. (Oltrabella et al., 2015). The pronephric endocytic defects are 
caused by the accumulation of PI(4,5)P2 and can be rescued by interfering with the activity of 
Pip5k, which is the kinase responsible for PI(4,5)P2 synthesis (Oltrabella et al., 2015). Loss of 
Ocrl causes several immune signaling channels to be activated, supporting the assumption that 
Ocrl mutants stimulate immune cells. This activation is due to defective endosomal trafficking 
among the many cellular functions for Ocrl. These findings explain not only the role of Ocrl, but 
also the contribution of membrane trafficking to the intrinsic function of immune cells, and suggest 
new approaches to explore the various symptoms of PD.   
In addition, PI(4,5)P2 accumulation in the abnormal vacuoles is observed in Ocrl 
knockdown cells. The ratio of PI(4,5)P2 found on endomembrane to that associated with the 
plasma membrane was significantly increased when Ocrl was depleted compared to control cells 
(Ben El et al., 2012). These results show that Ocrl regulates the enrichment of PI(4,5)P2 on the 




The D. melanogaster eye is composed of between 700 to 800 ommatidia made up of 
interommatidial bristle cells, cone cells, pigment cells and photoreceptor cells (Baker et al., 2001). 
Ocrl's inhibition and overexpression in developing eyes result in a rough eye phenotype that can 
be studied by the inhibition and overexpressed gene product for counteraction.  
I reduced the expression level of Ocrl in the D. melanogaster eye by expressing a UAS-
Ocrl-RNAi construct driven by GMR- GAL4. I hypothesized that reduced levels of Ocrl activity 
through RNA-interference would result in neurodevelopmental impairment in flies. I have 
observed that suppression of Ocrl activity has a detrimental effect on the D. melanogaster eye 
morphology. As predicted, loss-of-function of Ocrl in the fly eyes through the eye-specific 
expression of Ocrl-RNAi leads to a significant reduction in the number of ommatidia and 
interommatidial bristles. In addition, overexpression of Ocrl under the control of the eye-specific 
transgene, GMR-GAL4, causes a significant decrease in the number of ommatidia and 
interommatidial bristles when compared to the lacZ control in the eye of D. melanogaster. There 
have been no previous studies on the effects of Ocrl in D. melanogaster eyes. Therefore, the reason 
for this reduction in the number of ommatidia and interommatidial bristles is uncertain. However, 
it is plausible that the reduction in the number of ommatidia and interommatidial bristle suggests 
the changes in the level of Ocrl proteins affect the normal development of the eyes and seem to 
have a significant role in neurogenesis under normal cellular conditions. This may be assuming 
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that Ocrl's loss of function and overexpression induces cell growth inhibition required for normal 
development of the eye. 
Longevity assays were conducted to investigate the impact of the inhibition and 
overexpression of Ocrl. Inhibition of Ocrl using UAS-Ocrl-RNAiKK and UAS-Ocrl-RNAiGD in the 
motor neurons cause a significant decrease in the longevity of flies in comparison to control; 
however, no significant results were found by the use of UAS-Ocrl-RNAiHMS. This may be related 
to the efficiency of the RNAi transgene or its inhibitory transcript. In addition, inhibition of both 
gene Ocrl and park in the flies demonstrated a significant reduction in survival ability and 
indicated that reduced level of park and Orcl expression might have detrimental effects on lifespan, 
which is relatable to the symptoms of PD affected patients. 
Although I expected to observe the reduction in lifespan of flies by using the TH-GAL4 
and ddc-GAL4, no significant difference in the longevity of flies with the inhibition of Ocrl was 
found. This may include a counterbalancing effect with other parts of the pathway, including the 
individual interactions between Ocrl and other proteins. 
The co-expression of ddc-GAL4; UAS-park-RNAi showed a decrease in the lifespan of flies 
when Ocrl was inhibited as well as the co-expression of GMR-GAL4; UAS-park-RNAi showed a 
decrease in the number of ommatidia and interommatidial bristle of flies with inhibition of Ocrl. 
This line has neuron specific expression with a knockdown of parkin. With an inhibition of parkin 
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and Ocrl, there would be no regulation of Ocrl in the pathway. This may have detrimental effects 
and therefore cause the decrease in lifespan, ommatidia and interommatidial bristle number in the 
flies with the inhibition of both of these genes. The inactivation of parkin has been shown to 
contribute to the pathogenesis of Parkinson disease. 
Climbing analyses were conducted to determine the effects genes have on the locomotor 
ability of D. melanogaster over time due to the characteristics of PD that include resting tremor 
and rigidity. Inhibition of Ocrl using the three different RNAi in motor neurons, UAS-Ocrl-RNAiKK 
and UAS-Ocrl-RNAiHMS in dopaminergic neurons and UAS-Ocrl-RNAiHMS in dopaminergic and 
serotonergic, cause a significant decrease in the climbing ability of flies in comparison to the lacZ-
expressing control. No previous studies have been conducted on climbing ability associated with 
Ocrl. Therefore, the explanation for this reduction in climbing ability is unclear. However, I 
hypothesize that this reduction may be due to an increase in apoptosis or a decrease in cell growth 
during development. In addition, as dopaminergic neurons may die from apoptosis in PD, this 
reduction may be due to selective apoptotic death of these DA neurons and decreased cellular 
protection and survival. (Lev et al., 2003). Overexpression of Ocrl with dopaminergic neuron-
specific expression TH-Gal4 causes a significant difference in the longevity of flies, with Ocrl 
expressing flies living slightly longer than the control flies. From our research, it is unclear how 
Ocrl will extend the lifespan of flies when overexpressed in dopaminergic neurons, but Ocrl may 
play a protective role in these neurons by increasing the rate of apoptosis in the affected cell to 
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increase lifespan. I observed that there is a significant decrease in the climbing ability of flies with 
overexpression of Ocrl when crossed with the transgene line D42-GAL4. Ocrl mainly localizes in 
endolysosomal compartments. When it is knocked-down by RNAi, the cells abnormally 
accumulate PtdIns(4,5)P2 at the surface of giant endocytic vacuoles consequently delayed 
recycling of receptors, needed for the reabsorption of proteins (Kadhi et al.,2011). Therefore, a 
decline in climbing ability may be due to a potential increase in apoptosis when Ocrl is 
overexpressed. However, there was no significant decrease in the climbing ability of the flies when 
I used dopaminergic and serotonergic neuron-specific expression. There may be other contributing 
factors to this neurodegeneration in the Ocrl-associated pathway. In addition, UAS-OcrlEY may not 
be overexpressed as strongly with certain transgenes such as the TH-GAL4 and ddc-GAL4, used in 
this part of the experiment. 
Interestingly, it has been documented that Ocrl regulates the levels of PtdIns (4,5)P2 on 
human cell endosomes. Likewise, HeLa cells RNAi depleted for Ocrl present abnormal, enlarged 
endosomes enriched in PtdIns (4,5)P2 (Vicinanza et al., 2011). Therefore, regulation of PtdIns 
(4,5)P2 homeostasis and control of endosomal morphology by Ocrl proteins appears to be a 
general process conserved across evolution. In addition, the role of Ocrl proteins in the 
establishment of PtdIns (4,5)P2 homeostasis is underlying causes of the PD since the change in 
the levels of PtdIns(4,5)P2 have been shown to present in cells of PD patients (Dickson et al., 
2019). Inconclusive results for the loss of function in the dopaminergic neurons were observed. 
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Increases and decreases in lifespan and motor ability varied based on the transgene. The difficulties 
in Ocrl studies rely on the cells expressing INPP5B, an Ocrl paralog which has been shown to 
perform similar functions (Ben et al, 2012). Despite the inconclusive results I obtained, it is 
possible that the regulatory role of Ocrl and its involvement in the apoptosis activation may 
contribute to the results. One issue still remains to be solved to better understand the physiological 
role of Ocrl and to realize the molecular pathways linking mutations in Ocrl. Despite the 
ubiquitous expression of Ocrl in various cell types, the appearance of PD is limited to some nerve 
in the brain which gradually breaks down or dies. It is plausible that the compensatory activity of 
INPP5B (or of other corrector genes) in non-affected tissues and a requirement for full 5 
phosphatase activity in the affected tissues, would be the explanation for the greater need of these 
tissues through the endolysosomal pathway for efficient membrane trafficking. The major 
challenge over the next few years will be to explore the various ways to treat PD. Different 
strategies are possible, ranging from Ocrl replacement by gene therapy or haematopoietic stem 
cell transplantation to exon‑skipping therapy for specific mutations (Rendue et al., 2017), or the 
study of targets that are responsive to pharmacological manipulation. Ocrl is a phosphatase and 
many of the phenotypes that result from Ocrl's loss of function result from its substrate aggregation 
PI(4,5)P2. Moreover, several independent studies in cellular systems have shown that depletion of 
phosphoinositide kinases (either PIP5K or PI4K) can reduce the accumulation of PI(4,5)P2 in 
Ocrl‑depleted cells and rescue some of the phenotypes which is connected to the loss of Ocrl. 
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Thus, the development of selective, small molecule PIP5K inhibitors may enable the balance of 
PI(4,5)P2 to be restored in patients. Finally, to identify effective drugs, the availability of animal 
















This is the first characterization of Ocrl in a D. melanogaster model of Parkinson Disease. I have 
developed a new model of human Parkinson Disease to study Ocrl-related etiology of the disease. 
I expect that the knowledge gained through the determination of the pathways involved in 
Parkinson Disease in D. melanogaster will help identify potential new therapeutic approaches for 
human subjects. Further analysis is required to clearly interpret Ocrl’s associate with the familial 
PD genes such as PCR and microarray analysis. These analyses can identify genomic 
abnormalities that are associated with a wide range of developmental disabilities, including 
cognitive impairment and behavioral abnormalities. Therefore, a precise description of all genes 
involved in the progression of disease, their functions, interactions and their implications will 
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